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Chapter	  1	  
General	  Introduction	  on	  Aortic	  Stiffening	  and	  Hypertension:	  the	  Roles	  of	  Oxidative	  
Stress,	  Inflammation	  and	  Adaptive	  Immunity	  
 
Hypertension predisposes to cardiovascular and renal diseases, including stroke, myocardial infarction, 
heart failure and renal failure. In the United States, 30% of adults suffer from hypertension and another 
30% have pre-hypertension that commonly develops into overt hypertension in two years.1, 2 At age 70, 
70% of individuals are hypertensive. Although there are numerous antihypertensive agents available for 
the treatment of hypertension, only 65% of patients achieve goal blood pressure.3 Treatment often 
requires multiple medications, especially in patients with diabetic nephropathy.4 
Despite extensive research for the past half-century, the etiology of most cases of human hypertension 
remains undefined. Monogenic hypertension generally involves mutations of transporters in the distal 
nephron and accounts for less than5% of patients.5,6 Other correctable causes of hypertension can 
occur as a consequence of adrenal adenoma, renal artery stenosis or pheochromocytoma, however, 
these are uncommon. Other cases of hypertension are of unknown etiology and are referred to as 
“essential”. 
Traditionally, abnormalities of the resistance arteries with diameter less than 200 µm are believed to 
increase systemic vascular resistance, which is a common feature of almost all adults with 
hypertension.. In keeping with this, vasodilators such as calcium channel blockers and nitrates lower 
blood pressure by vasodilatory effects. Hypertension also changes vascular structure, leading to 
thickening of vascular wall and loss of capillaries.7 
	  
1.1	  The	  role	  of	  aortic	  stiffening	  in	  hypertension:  In contrast to the traditionally held belief that 
hypertension is entirely due to the resistance arterioles, large arteries have been recently recognized to 
play an important role the development of hypertension, particularly systolic hypertension. The thoracic 
aorta functions as a buffering system that absorbs the force of the ejected blood and blunts blood 
pressure elevation during systole. During diastole, the blood volume stored by this capacitance function 
is discharged into the downstream resistance circulation and together with returning waves from the 
peripheral circulation, maintains diastolic pressure and perfusion. Increase in large artery stiffness 
increases characteristic aortic impedance, enhances the speed of returned waves from the periphery 
and is associated with a progressive increase in systolic pressure, a decline in diastolic pressure and 
an increase in pulse wave velocity (PWV). Apparent arterial pressure pulse is the sum of forward 
traveling wave and reflected wave and pulse wave velocity is the speed at which it travels down the 
arterial system. PWV can be measured in humans by a variety of non-invasive methods, including MRI 
and ultrasound. Arterial stiffening not only contributes to hypertension, but also has significant 
implications for subsequent morbidity and mortality. 
Clinically, aortic stiffening accompanies atherosclerosis, diabetes, obesity, cigarette smoking and 
autoimmune disease. While aortic stiffening is commonly encountered in hypertension, the causal 
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relationship between aortic stiffening and blood pressure elevation has been controversial. Abboud and 
Huston employed a mathematical method to estimate vascular stiffness in humans and concluded that 
hypertension is not caused by aortic stiffening, but that it is a cause of aortic stiffening.8 Aatola et al 
found that elevated childhood blood pressure tracks to adulthood and predicts the development of 
arterial stiffness. However, in high fat/high sucrose-induced obesity mice, pulse wave velocity increases 
within 1 month of the initiation of diet while hypertension develops by 5 month.9 In support of this, 
recent studies in the Framingham heart cohort demonstrate that higher aortic stiffness, forward wave 
amplitude and augmentation index precede the development of hypertension at a later time point.10 
	  
1.2	  Molecular	  characteristics	  of	  arterial	  stiffening: Post mortem analyses have shown that human 
hypertension is associated with a striking aortic medial fibrosis as indicated by Masson’s trichrome blue 
staning.11 Atherosclerosis, diabetes, age and renal disease are associated with vascular fibrosis in 
these subjects. The degree of media fibrosis correlates with pre-mortem pulse pressure and 
hypertension. In experimental hypertension, hypertension induces vascular fibrosis via the expression 
of collagen type I, type III and fibronectin.12 A decrease in elastin content was associated with 
parameters of arterial stiffness in males but not females in a study of non-human primtes.13 In keeping 
with this, mice with elastin haploinsufficiency (Eln+/-) exhibit arterial stiffening and hypertension.14 
Likewise, impaired fetal synthesis of elastin in large arteries is associated with permanent changes in 
mechanical properties of these vessels and predisposes to hypertension and left ventricular 
hypertrophy in subjects with low birth weight. Either loss of aortic elastin or elastin fragmentation 
redistributes circumferential wall stress to less compliant collagen, leading to vascular stiffening.  
	  
1.3	  The	  role	  of	  oxidative	  stress	  in	  hypertension: The term oxidative stress refers to an imbalance 
between the production of reactive oxygen species (ROS) and antioxidant defenses.15 ROS mediate 
pathological changes in the brain, the kidney and blood vessels associated with the genesis of chronic 
hypertension. In an initial study, Nakazono and colleagues showed that bolus administration of a 
modified form of SOD acutely lowered blood pressure in hypertensive rats.16 Membrane-targeted forms 
of SOD and SOD mimetics such as tempol lower blood pressure and decrease renovascular resistance 
in hypertensive animal models.17 There is ample evidence suggesting that ROS not only contribute to 
hypertension but that the NADPH oxidase is their major source.18, 19 Components of this enzyme 
system are upregulated by hypertensive stimuli, and NADPH oxidase enzyme activity is increased by 
these same stimuli. Moreover, both angiotensin II-induced hypertension and deoxycorticosterone 
acetate (DOCA)-salt hypertension are blunted in mice lacking this enzyme.18-20 Despite the evidence 
that oxidative stress contributes to hypertension, the mechanisms involved are not well understood. 
 
While scavenging of ROS decreases blood pressure in experimental hypertension, clinical trials with 
high dose antioxidants have been disappointing. Several large clinical trials have failed to show 
beneficial effects of either vitamin C or vitamin E supplementation in cancer, cardiovascular disease 
and neurodegenerative diseases. A recent meta-analysis of 50 randomized trials including almost 
300,000 patients confirmed the futility of treatment with a variety of antioxidants in cardiovascular 
disease.21 Surprisingly, large doses of beta-carotene, vitamin A and vitamin E have paradoxically 
worsened cardiovascular outcomes in some studies.22 The failure of antioxidants in humans might 
reflect the low rate constant of vitamins such as E and C with superoxide and related ROS, the inability 
to target subcellular sites where ROS are formed, and the fact that some ROS have beneficial effects in 
cell signaling and survival. 
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1.4	  The	  potential	  role	  of	  ROS	  in	  aortic	  stiffening: Oxidative events have been associated with 
various perturbations of elastin and collagen. Oxidative stress promotes the degradation of elastin fiber 
components from the extracellular matrix (ECM).23 This may be due to the activation of matrix 
metalloproteinases with elastase activity.24 As an example, oxidative radicals generated by the 
xanthine/xanthine oxidase complex activate the MMP-2 in coronary smooth muscle cells.25 In the 
studies of emphysema, a condition characterized by the fragmentation of elastin fibers, the loss of 
Cu/Zn superoxide dismutase (SOD) activity due to copper deficiency results in severe emphysema in 
the Syrian Golden Hamster.26 In contrast to this, overexpression of Cu/Zn SOD protects from the 
development of emphysema induced by cigarette smoking or elastase perfusion.27 Interestingly, the 
severity of emphysema is associated with parameters of arterial stiffness in patients with chronic 
obstructive pulmonary disease, suggesting that oxidative stress could affect elastin in both the lung and 
blood vessels via similar mechanisms. 
ROS also affect expression and structure of collagen in the extracellular matrix. Superoxide stimulates 
production of collagen type I and type III in fetal human fibroblasts and this is prevented by superoxide 
dismutase.28 A recent study elegantly demonstrated that hydrogen peroxide (H2O2), generated via Nox 
4, mediates the differentiation of myofibroblasts and their production of ECM components in response 
to TGF-β during lung injury.29 The pro-fibrogenic effects of ROS are abrogated either by 
pharmacological inhibition of Nox 4 or by its genetic deletion, supporting the concept that ROS 
produced by NADPH oxidase promotes collagen deposition and lung fibrosis. ROS promote formation 
of advanced glycation products (AGEs),30 which react with ECM components especially collagen; and 
drugs that break AGE-mediated cross-links decrease arterial stiffness in humans and experimental 
animals.31, 32 In the setting of oxidative stress, AGE-mediated protein cross-linking may act in concert 
with increased collagen deposition to promote aortic stiffening during aging.   
	  
1.5	  The	  interactions	  of	  oxidative	  stress,	  inflammation	  and	  immunity	  in	  hypertension: A variety 
of mechanical, hormonal and cellular factors common to the hypertensive milieu promote the 
development of inflammation and in many cases these involve oxidant events. Oxidative stress and 
inflammation can cause one another. A hallmark of many diseases associated with vascular 
inflammation, such as aging, atherosclerosis and hypertension, is increased vascular ROS 
production.33-35 Studies in experimental animals have implicated ROS formation in inflammation of the 
vasculature, lung, skin and other tissues. As an example, mechanical stretch activates both endothelial 
and vascular smooth muscle production of ROS, which in turn can activate pro-inflammatory 
transcription factors such as NF-κB.36, 37 This leads to expression of adhesion molecules such as 
VCAM-1 and ICAM-1 and chemokines such as MCP-1 and RANTES which recruit T cells, 
macrophages and circulating fibrocytes to blood vessels.38-40 ROS increase permeability of the vascular 
endothelium, facilitating the infiltration of these inflammatory cells.41 The infiltrating inflammatory cells 
that enter target tissues may promote additional ROS generation, exacerbate oxidant injury and 
eventually result in fibrotic changes in the heart, kidney and blood vessels.33, 42 
	  
1.6	  T	  cell-­‐mediated	  adaptive	  immunity	  in	  hypertension: There is strong evidence that adaptive 
immunity contributes to hypertension. As an example, Svendson showed that the delayed phase of 
DOCA-salt hypertension was blunted in thymectomized animals.43 Pre-eclampsia is associated with an 
increase in lymphocyte markers and the cytokine profile of natural killer lymphocytes in the uterus.44 
Interestingly, a recent analysis of almost 6000 people with AIDS (with reduced CD4+ cells) showed that 
the incidence of hypertension was significantly lower than the general population matched non-infected 
individuals.45 Treatment with highly active anti-retroviral therapy for 2 years restored the incidence of 
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hypertension to that of the control population. This finding might reflect a need for functioning helper T 
cells in the development of hypertension.  
During the past several years, we have added significantly to the concept that adaptive immunity plays 
an important role in hypertension. Studies from my mentor’s laboratory have shown that hypertensive 
stimuli such as angiotensin II, increased salt and aldosterone, catecholamines lead to formation of 
neoantigens that promote T cell activation.33, 46, 47 T cells with an effector phenotype infiltrate the 
vasculature and the kidney and release cytokines such as IL-17A and IFN-γ that, together with the 
direct effects of these hypertensive stimuli, promote formation of reactive oxygen species (ROS) in 
these peripheral sites,33, 39, 48 vasoconstriction and renal sodium retention, ultimately leading to severe 
hypertension.49 The deficiency of T lymphocytes or perturbations of IL-17A or IFN-γ signaling blunt 
angiotensin II-induced hypertension, ameliorate vascular inflammation and target organ damage.33, 39, 42 
In p47phox-/- mice, and in animals treated with antioxidants, hypertensive responses to angiotensin II 
are markedly blunted.16, 17, 50 Our recent data indicate that ROS formation is increased in dendritic cells 
(DCs) and likely plays a role in this pathway.47 Isoketal accumulation is associated with DC production 
of IL-6, IL-1β and IL-23 and an increase in costimulatory proteins CD80 and CD86. These activated 
DCs promote T cell, particularly CD8+ T cell, proliferation; production of IFN-γ and IL-17A; and 
hypertension. Moreover, isoketal scavengers prevented angiotensin II-induced hypertension and these 
hypertension-associated events. 	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Chapter	  2	  
Inflammation	  and	  Mechanical	  Stretch	  Promote	  Aortic	  Stiffening	  in	  Hypertension	  
Through	  Activation	  of	  p38	  MAP	  Kinase	  
	  
2.1	  Chapter	  Abstract	  
Aortic stiffening commonly occurs in hypertension and further elevates systolic pressure. Hypertension 
is also associated with vascular inflammation and increased mechanical stretch. I sought to determine 
the role of these factors in aortic stiffening. Chronic angiotensin II infusion caused marked aortic 
adventitial collagen deposition, as quantified by Masson’s trichrome Blue staining and biochemically by 
hydroxyproline content, in wild-type (WT) but not in Recombination Activation Gene-1 deficient (RAG-1-
/-) mice. Aortic compliance, defined by ex-vivo measurements of stress-strain curves, was reduced by 
chronic angiotensin II infusion in WT mice (p<0.01) but not in RAG-1-/- mice (p<0.05). Adoptive transfer 
of T cells to RAG-1-/- mice restored aortic collagen deposition and stiffness to values observed in WT 
mice. Further studies indicated that CD8+ and to a lesser extent CD4+ T cells contribute to aortic 
stiffening and collagen deposition. Mice lacking IL-17a were also protected against aortic stiffening. In 
additional studies, I found that blood pressure normalization, by treatment with hydralazine and 
hydrochlorothiazide completely prevents angiotensin II-induced vascular T cell infiltration, aortic 
stiffening and collagen deposition.  Finally, I found that mechanical stretch induces expression of 
collagen 1α1, 3α1 and 5a1 in cultured aortic fibroblasts in a p38 MAP kinase-dependent fashion, and 
that inhibition of p38 prevented angiotensin II-induced aortic stiffening in vivo. IL-17a also induced 
collagen 3a1 expression via activation of p38 MAP kinase.  Our data suggest a pathway in which 
inflammation and mechanical stretch lead to vascular inflammation that promotes collagen deposition. 
The resultant increase in aortic stiffness likely further worsens systolic hypertension and its attendant 
end-organ damage. 
Keywords: Inflammation, mechanical stretch, collagen deposition and aortic stiffening 
 
2.2	  Introduction	  
Normally the capacitance property of the aorta blunts blood pressure elevation during systole and 
maintains diastolic pressure and tissue perfusion during diastole. Loss of this windkessel function in the 
proximal aorta causes an increase in systolic pressure, a decline in diastolic pressure and an increase 
in pulse wave velocity.51 The augmentation of systolic pressure caused by aortic stiffening increases 
the incidence of stroke, renal failure and myocardial infarction. Aortic stiffening is associated with aging, 
insulin resistance, diabetes, atherosclerosis and hypertriglyceridemia.52-55 Importantly, hypertension per 
se causes aortic stiffening, leading to progressive elevation of systolic pressure. Thus, aortic stiffening 
not only contributes to hypertension but also portends cardiovascular morbidity and mortality.56, 57 
The precise mechanisms underlying aortic stiffening remain undefined.  Clinical studies suggest that 
inflammation and arterial stiffness are related.58-61 Patients with inflammatory diseases such as lupus 
erythematosus, rheumatoid arthritis and psoriasis have increased pulse wave velocity.62-64 Data from 
our laboratory and others have shown that T cells and T cell-derived cytokines are important in 
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development of hypertension.33, 39 We have previously found that Recombination Activation Gene-1 
deficient (RAG-1-/-) mice develop blunted hypertension in response to angiotensin II, DOCA-salt 
challenge and norepinephrine.46 The RAG-1 gene encodes a gene responsible for recombining the 
variable regions of the T cell receptor and immunoglobulins and in its absence mice fail to develop 
either B cells or T cells. Adoptive transfer of T cells restores hypertension in RAG-1-/- mice, indicating a 
critical role of these cells. Recently, deletion of the RAG-1 gene in Dahl Salt-sensitive rats has been 
shown to lower blood pressure and to reduce renal injury upon salt feeding.65 Other studies have 
shown that T cells- derived cytokines also contribute to hypertension, likely by promoting vascular 
dysfunction and renal injury.39, 42, 66 One such cytokine is interleukin 17a (IL-17a), which is produced by 
a subset of pro-inflammatory CD4+ T cells, or TH17 cells. Mice lacking IL-17a have blunted 
hypertension and reduced aortic production of ROS following angiotensin II infusion. Recent studies 
have also shown that administration of IL-17a to mice causes hypertension and reduces endothelium-
dependent vasodilatation, at least in part by activating Rho kinase.67 IL-17a also promotes collagen 
deposition and contributes to fibrosis in other tissues and conditions.68-70 
In the present study I sought to examine mechanisms responsible for aortic stiffening in hypertension. 
In particular I examined the role of adaptive immunity mediated by T cells and their cytokines and the 
direct effects of mechanical stimulation by blood pressure lowering and by exposing aortic fibroblasts to 
hypertensive levels of stretch. I identify a novel pathway that promotes striking aortic adventitial 
collagen deposition and vascular stiffening.  
 
2.3	  Materials	  and	  methods	  
Animals:  Wild type, Rag-1-/-, CD4-/- and CD8-/- mice were obtained from Jackson Laboratories on a 
C57Bl/6 background.  IL-17A-deficient (IL-17a-/-) mice were produced as previously described.  At 3 
months of age, these animals were implanted with telemetry units for measurement of blood pressure.  
One week later osmotic minipumps were implanted subcutaneously for infusion of angiotensin II (490 
ng/kg/min) or vehicle for 2 weeks.  Blood pressure was recorded for 10 minutes every hour for the 
duration of the experiments (i.e. three days prior to osmotic minipump implantation and until the end of 
angiotensin II infusion at Day 14).  Hydralazine and hydrochlorothiazide were given in drinking water 
(320 mg/L and 60 mg/L) to normalize blood pressure at the same time as the 2-week angiotensin II 
infusion or to reverse established hypertension in the last two weeks of 4-week angiotensin II infusion. 
In deoxycorticosterone acetate (DOCA)-salt-treated mice, 100 mg deoxycorticosterone acetate pellet 
were implanted subcutaneously following uninephrectomy.  These mice were subsequently maintained 
on drinking water with 0.9% NaCl for three weeks.  P38 MAP kinase inhibitor SB203580 was dissolved 
in 50% DMSO and administered at 10 mg/kg/day via i.p. injections.  At the end of each experiment, 
mice were sacrificed with CO2 inhalation and the chest was rapidly opened and the superior vena cava 
sectioned.  A catheter was placed in the left ventricular apex and the animals were perfused at a 
physiological pressure with Krebs-Hepes buffer until the effluent from the vena cava was cleared of 
blood.  The Institutional Animal Care and Use Committee approved all experimental protocols. 
Materials: Antibodies used for flow cytometry included: FITC anti-CD45; PerCP anti-CD45; PE anti-
CD3e; FITC anti-CD3e; APC anti-CD3; APC anti-CD4; PerCP anti-CD8a; PE-Cy7 anti-CD8a.  These 
were obtained from Becton Dickinson.  Isolation kits for pan-T cells were from either Miltenyi biotech or 
Invitrogen.  RNA isolation kits were purchased from Qiagen.  PCR array kits for aortic matrix gene and 
adhesion molecules were purchased from SABiosciences.  Primers for quantitative polymerase chain 
reactions and reverse transcription kits were obtained from Applied Biosystems, Life Technologies 
(Grand Island, NY).  Rabbit anti-mouse monoclonal antibody for phospho-p38 and p38 were obtained 
from Cell Signaling (Boston, MA).  Secondary goat anti-rabbit antibody was purchased from Bio-Rad 
(Hercules, CA). SB203580 compound was purchased from Selleckchem (Houston, TX).  Seventy-
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micron filters for cell separation were obtained from BD Biosciences.  All other reagents were obtained 
in the highest grade possible from Sigma-Aldrich (St. Louis, MO).  
Determination of aortic compliance: Using a commercially available system (Danish Myograph 
Technology, Model 110P) segments of the thoracic aorta were mounted on 0.7 mm cannulas and 
extended to the in situ length.  Vessels were placed in calcium-free buffer to eliminate active tone.  
Intraluminal pressure was increased in a step-wise fashion while video microscopy was used to follow 
outer and inner diameter.  Diameters were recorded with every increment of 25 mmHg from 0 to 200 
mmHg.  The maximal intraluminal pressure was 200 mmHg because both the lumen diameter and 
outer diameter reach a plateau beyond this pressure.  Pressure diameter curves were constructed for 
calculation of vascular compliance, in which the increment of vessel diameter from 0 mmHg was plotted 
against pressure. The traditional stress-strain relationship was determined as previously described,71 
where a leftward shift indicates aortic stiffening.  Circumferential stress (σ) was calculated from the 
following formula:  
Formula 1:  σ=(P x ID)/(2WT). 
Where P = intraluminal pressure, ID = inner diameter, and WT = wall thickness. Intraluminal pressure 
was converted from millimeters of mercury to dynes per square centimeter (1 mmHg = 1.334 x 103 
dynes/cm2).  Circumferential strain (ε) was calculated from the formula: 
Formula 2:  ε= ΔOD/OD0 
Where OD0 refers to the original outer diameter, defined as diameter at 0 mmHg.  ΔOD represents the 
increase in outer diameter from OD0 at each pressure level. 
Measurement of aortic collagen and elastin:  Aortic collagen was visualized by Masson’s Trichrome 
staining.  Elastin was visualized by Verhoeff Van Gieson’s elastica staining.  The effect of angiotensin 
II-induced hypertension on aortic collagen was determined by measurement of tissue hydroxyproline as 
described previously72.  In separate vessels, elastin content was determined as previously described73, 
74, with minor modifications. Briefly, insoluble elastin was separated from all other soluble proteins by 
hydrolysis in 0.1N NaOH at 90°C for 45 minutes.  Both the soluble and insoluble fractions were further 
digested in 6N HCl at 105°C for 48 hours, neutralized and assayed for ninhydrin content. 
T cell adoptive transfer:  Pan T cells, CD4+ T cells or CD8+ T cells were isolated using negative 
selection from spleens of age-matched wild type mice, and 107 cells were resuspended in 200 µL of 
saline and injected by tail vein into RAG-1-/- mice. Three weeks following adoptive transfer, chronic 
angiotensin II infusion (490 ng/kg/min) was performed for 14 days.  Blood pressure, aortic stiffening and 
collagen deposition were determined in these mice as described above.   
Flow cytometry: Following removal, spleens and aortas were rapidly minced and digested using 
collagenase type XI (125 U/mL), collagenase type I-S (450 U/mL), and hyaluronidase I-S (60 U/mL) in 
20 mM Hepes-PBS buffer containing calcium and magnesium for 30 min at 37°C.  The tissues were 
further dispersed using repeated pipetting and the resultant homogenate was passed through a 70-µm 
sterile filter, yielding single-cell suspensions.  The cells were washed with PBS and resuspended in 2 
mL 40% Percoll.  Two mL of 60% Percoll was then added to the resultant gradient and centrifuged at 
2400 RPM for twenty minutes.  The uppermost layer of the gradient, containing fat and non-cellular 
material not removed by the filter was discarded and cells in the lower portion of the gradient was 
counted and stained for subsequent flow cytometry.       
	   	   	  	  
8	  	  
Cell culture: Primary mouse aortic fibroblasts were obtained from Cell Biologics, (Chicago, IL) and low-
passage cells were used for cytokine incubation and real-time PCR studies.  Briefly, cells were cultured 
in media provided by the supplier on plates coated with 0.2% gelatin until 90% confluent.  The media 
was changed from 5% to 0.5% FBS for 24 hours prior to experiments.  Cells were exposed to 5% or 10% 
cyclical stretch to mimic mechanical stretch at normotensive and hypertensive conditions using the 
Flexcell FX-5000TM Tension System (Hillsborough, NC).  In additional experiments, p38 MAP kinase 
inhibitor was added to fibroblasts treated with IL-17a (100 ng/mL) or 10% cyclical stretch. 
Real-time PCR: RNA was extracted from freshly harvested aorta or cell culture using Qiagen RNeasy 
mini kit. PCR array was performed to examine the expression of 84 genes for aortic matrix and 
adhesion molecules.  Additional real-time PCR reactions were performed to examine selected fibrotic 
genes in cultured fibroblasts, including collagen 1a1, 3a1, 5a1, fibronectin-1, TGF-β, ribosomal 18s and 
β-actin.  Real time quantitative PCR was performed on Applied Bioscience System 7500 Fast. 
Western Blot: p38 MAPK was quantified in angiotensin II-treated aortas and mouse fibroblasts 
stretched with different treatments. Freshly isolated aortas or cultured cells were homogenized in Ripa 
lysis buffer with proteinease inhibitor and phosphatase inhibitors (Roche).  Monoclonal rabbit anti-
mouse antibodies were used to detect phosphorylated p38, total p38, β-actin and β-tubulin at a 
concentration of 1:1000.  Polyclonal goat anti-rabbit antibody was used as the secondary antibody 
(1:4000).  Densitometry was performed on Biorad ChemiDocTM XRS+ imaging system.   
Statistical analysis: Data in the manuscript are expressed as the mean ± SEM.  Comparisons of blood 
pressure over time were made using one-way ANOVA for repeated measures, followed by a Student 
Newman Keuls post hoc test when significance was indicated.  Compliance curves and stress-strain 
curves were also compared using ANOVA for repeated measures.  To compare the effect of 
angiotensin II on parameters other than blood pressure, two-way ANOVA was employed, as indicated.  
The effects of adoptive transfer of pan T cells or antihypertensive treatment on collagen deposition or 
aortic inflammation were compared using one-way ANOVA.  P values are reported in the figures. 
 
2.4	  Results	  
2.4.1 Effect of angiotensin II-induced hypertension on aortic collagen and elastin content:  role 
of T cells. Two matrix components that predominantly modulate tissue compliance are collagen and 
elastin. I performed initial studies to determine how hypertension affects these and to understand the 
role of T cells in this response. Using Masson’s Trichrome staining, I observed that collagen is 
predominantly localized to the adventitia of the aorta of sham infused mice. During angiotensin II 
infusion, a striking accumulation of collagen in the aortic adventitia occurred. This degree of adventitial 
collagen deposition was often equivalent to the media (Figure 1A and 1B). By planimetry, adventitial 
collagen area was increased from 3.8×104 µm2 to 13.6×104 µm2 by angiotensin II treatment.  To directly 
quantify aortic collagen, I measured hydroxyproline content, which was 25 ± 9 ng/µg of total protein in 
WT mice and was doubled by chronic angiotensin II infusion (Figure 1C). Thus, by both histochemical 
staining and biochemical analysis, I found that angiotensin II-induced hypertension is associated with a 
2-3-fold increase of aortic collagen content, predominantly localized to the adventitia.    
I and others have established a role of T cells in hypertension.15,16 Moreover, the T cell derived cytokine 
IL-17 contributes to hypertension and has been shown to promote collagen deposition in experimental 
scleroderma.17  I therefore examined the role of T cells in aortic stiffening.  As in previous studies, I 
found that the hypertensive response to angiotensin II is blunted in RAG-1-/- mice (Figure 2A and B).  In 
addition, the increase in aortic collagen content caused by angiotensin II, as detected by either 
Masson’s trichrome staining or by hydroxyproline assay, was blunted in RAG-1-/- mice (Figure 1A-C).  
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Five weeks following adoptive transfer of pan T cells, flow cytometry documented a stable population of 
these cells in RAG-1-/- mice (Figure 2C).  In keeping with our prior studies, T cell adoptive transfer 
restored the hypertensive response to angiotensin II in RAG-1-/- mice (Figure 2D and 1E).  Importantly, 
adoptive transfer of T cells to RAG-1-/- mice also restored the aortic collagen deposition caused by 
angiotensin II to levels observed in WT mice (Figure 1A-C). Despite these fibrotic changes in the aorta, 
I did not observe collagen deposition in the mesenteric arteries of WT or RAG-1-/- mice treated with 
angiotensin II (Figure 3). 
Van Gieson’s Elastica staining did not reveal a qualitative difference in elastin between sham or 
angiotensin II-treat mice or in RAG-1-/- mice (Figure 1A). Angiotensin II-induced hypertension was 
associated with hypertrophy of medial cells, causing a greater separation of elastin laminae. 
Biochemical analysis also did not reveal differences in the absolute amount of elastin between sham 
and angiotensin II-treated WT or RAG-1-/- mice, or an effect of T cell adoptive transfer (Figure 1D). 
When normalized to total protein, relative elastin levels were decreased by angiotensin II in both mouse 
strains (Figure 2F), but this could be attributed to the striking increase in total aortic protein associated 
with angiotensin II-induced aortic hypertrophy (Figure 2G).   
2.4.2 Angiotensin II-induced hypertension causes dramatic changes in the expression of the 
aortic matrix genes: In addition to collagen and elastin, numerous other matrix proteins can influence 
vascular stiffness. I therefore performed a PCR array to characterize expression of 84 aortic matrix 
genes related to fibrosis and remodeling. In response to angiotensin II infusion, 17 out 84 genes were 
significantly upregulated while no genes were down regulated (Table 2). Among these, collagen 1a1 
and MMP-2 were upregulated by more than 8 fold and collagen 3a1 by 7 fold.  MMP-11, 
thrombospondin-1, thrombospondin-2 and secreted acidic cysteine rich glycoprotein (Sparc) were 
upregulated by 4-5 fold.  I also found more than 3 fold upregulation for collagen 5a1 and MMP-14. 
Surprisingly, the potent pro-fibrotic cytokine, TGF-β1, was not altered in angiotensin II-induced 
hypertension.  
2.4.3 Hypertension reduces aortic compliance – role of T cells: Additional studies were performed 
to measure compliance of isolated segments of the descending thoracic aorta. Chronic angiotensin II 
infusion caused marked stiffening of the thoracic aorta in WT mice, as evidenced by a downward shift 
of the compliance curve (Figure 4A) and leftward shift of the stress-strain relationship (Figure 4B). In 
contrast, in RAG-1-/- mice, chronic angiotensin II infusion had essentially no effect on aortic stiffness. 
Adoptive transfer of T cells to RAG-1-/- mice restored the increase in aortic stiffening caused by 
angiotensin II (Figure 4C and 4D). Analysis of the changes in vascular inner and outer diameter 
showed that these increased in parallel in vessels from sham treated mice as intraluminal pressure was 
increased. In contrast, following angiotensin II infusion, the increase in outer diameter was constrained 
in aortas from WT mice, but not in aortas from RAG-1-/- mice (Figure 4E and 4F). 
To determine the relative contribution of T cell subtypes, I examined the effect of angiotensin II infusion 
in CD4-/- and CD8-/- mice. The increase in collagen caused by angiotensin II was blunted in mice lacking 
either T cell subtype, but was most striking in mice lacking CD8+ T cells as evidenced by both Masson’s 
trichrome staining and by hydroxyproline assay (Figure 5A-C). In addition, CD4-/- and CD8-/- mice were 
both partially protected against the development of aortic stiffening caused by angiotensin II (Figure 5D-
5G). In additional studies, I performed adoptive transfer of CD4+ T cells or CD8+ T cells to RAG-1-/- mice 
and then infused angiotensin II three weeks later. Neither cell type alone increased aortic stiffness or 
collagen content significantly (Figure 6). These data indicate that both cell types are required and likely 
interact to mediate hypertension-related aortic stiffening.  
I have previously shown that that mice lacking IL-17a are protected against the development of 
hypertension, aortic inflammation and angiotensin II-induced vascular oxidative stress.39 In the present 
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study, I found that IL-17a-/- mice are also protected against aortic collagen deposition (Figure 7A-C) and 
aortic stiffening (Figure 7D and E) in response to chronic angiotensin II infusion. 
I have previously shown that T cells play a role in models of hypertension other than angiotensin II 
infusion, including DOCA-salt hypertension and norepinephrine-induced hypertension.33, 46 To 
determine if the reduced adventitial collagen deposition and aortic stiffening in RAG-1-/- mice are 
specific to angiotensin II, I also studied deoxycorticosterone acetate (DOCA)-salt-induced hypertension, 
which is characterized by low levels of circulating angiotensin II. As shown in Figure 8, while WT mice 
developed marked collagen deposition and aortic stiffening in response to DOCA-salt challenge, RAG-
1-/- mice were protected from these changes. These data suggest that T cells contribute to aortic 
stiffening in forms of hypertension other than that caused by angiotensin II. 
2.4.4 Aortic stiffening is dependent on blood pressure elevation:  In clinical studies, aortic 
stiffening is commonly associated with hypertension; however, the causal relationship remains unclear. 
To address the possible role of pressure elevation in the genesis of aortic stiffening, I normalized blood 
pressure in angiotensin II-infused mice by adding hydralazine (320 mg/L) and hydrochlorothiazide (60 
mg/L) to the drinking water. As shown in Figure 9A and 9B, concurrent hydralazine and 
hydrochlorothiazide treatment completely prevented the elevation of blood pressure.  This treatment 
also protected against adventitial collagen deposition (Figure 9C-E). More importantly, the shifts in 
compliance and stress-strain curves were prevented by this treatment regimen (Figure 9F and 5G). 
Interestingly, I found that hydralazine and hydrochlorothiazide also abrogated T cell infiltration and 
inflammation in the aortas of angiotensin II-infused mice (Figure 9H-L). Collectively, these data suggest 
that aortic stiffening and vascular inflammation are at least in part due to mechanical effects of 
hypertension.   
To determine whether normalization of blood pressure in established hypertension could reverse 
collagen deposition and aortic stiffening, hydralazine and hydrochlorothiazide treatment was 
administered from day 15 to day 28 during a 4-week angiotensin II infusion. Although this successfully 
normalized blood pressure during the last two weeks of angiotensin II infusion, it failed to reverse 
adventitial collagen deposition and aortic stiffening (Figure 10). These data suggest that hypertension 
might cause irreversible large vessel fibrosis and remodeling. 
2.4.5 Aortic fibroblasts express collagen in response to IL-17a and hypertensive mechanical 
stretch:  The above experiments suggest that both inflammation and mechanical forces contribute to 
aortic stiffening. To differentiate between the direct effect of mechanical stretch and the inflammatory 
cytokine IL-17a, I performed additional studies using cell culture. Because I found aortic collagen 
deposition in hypertension occurs largely in the adventitia, I studied aortic fibroblasts, which represent 
the predominant cell type of the adventitia. I focused these studies on the collagen subtypes identified 
in the real-time PCR array. Fibroblasts were exposed to either 5% or 10% stretch, mimicking levels of 
mechanical stretch observed in the setting of normal and elevated blood pressures, or were exposed to 
IL-17a (100 ng/mL) for 36 hours. I found that while IL-17a had no effect on the mRNA expression of 
collagen 1a1, 10% mechanical stretch doubled expression of this subtype beyond that observed with 5% 
stretch (Table 2). Collagen 3a1 was increased by more than 4-fold by IL-17a and by more than 3-fold in 
response to 10% stretch. Collagen 5a1 mRNA expression was increased approximately 2-fold by IL-
17a and by 10% stretch, but was not further increased by the combination of this cytokine and stretch. 
The addition of angiotensin II had minimal effect on these responses except for collagen 3a1, where it 
doubled the effect of 10% stretch. These experiments show that the hypertensive milieu, which includes 
increased vascular stretch, inflammatory cytokines such as IL-17a and angiotensin II interact to 
modulate aortic fibroblast collagen production. 
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2.4.6 Activation of p38 MAPK is required for collagen expression and aortic collagen deposition 
induced by stretch and inflammation in vitro and in vivo: p38 MAPK has been implicated in the 
induction of collagen expression and fibrosis in different hypertensive models.75-78 Interestingly, both 10% 
stretch and IL-17a at 100 ng/mL induced p38MAP kinase phosphorylation in aortic fibroblasts  (Figure 
11A-C). Moreover, inhibition of p38 MAP kinase with SB203580 prevented the increase in mRNA for 
collagens 1a1, 3a1 and 5a1 caused by stretch (Figure 11D-F). In contrast, SB203580 inhibited IL-17a-
induced expression of collagen 3a1 but not collagen 5a1 (Figure 11G-I). I also found that angiotensin II-
induced hypertension increased p38 MAPK phosphorylation in thoracic aortas, and that this was 
prevented by the normalization of blood pressure (Figure 12A-C). To gain insight into the role of p38 
MAPK in vivo, I treated mice with SB203580 (10 mg/kg/day, i.p.) concurrently with angiotensin II. 
SB203580 reduced the hypertension caused by angiotensin II (Figure 12D and E). More importantly, 
SB203580 prevented collagen deposition (Figure 12F-H) and prevented the shift in aortic compliance 
and stress strain relationships caused by angiotensin II (Figure 12I and J). Of note, inhibition of p38 
MAP kinase induced the formation of aneurysm in mice receiving angiotensin II infusion, suggesting 
collagen deposited in the aortic adventitial in hypertension might protect against destructive changes in 
the arterial wall (Figure 13). These data show that p38 MAP kinase is responsive to stretch and 
inflammation, and thus plays a central role in mediating collagen expression in cultured fibroblasts and 
in inducing aortic stiffness in vivo.   
 
2.5	  Discussion	  
In the present study, I identified novel mechanisms of aortic stiffening associated with hypertension as 
delineated in the scheme shown in Figure 14. Our data indicate that elevation of blood pressure and 
the attendent increase in vascular stretch leads to an inflammatory process characterized by infiltration 
of T cells and activation of p38 MAP kinase.  These events lead to a striking deposition of collagen in 
the aortic adventitia, with scattered amounts of collagen in the media.  This is associated with a marked 
alteration in aortic complaince, characterized by a leftward shift in the stress strain relationship and a 
downward relationship between aortic distending pressure and diameter.  In vivo, this increase in aortic 
stiffness leads to a loss of the Windkessel or capacitance function of the aorta, increasing systolic 
pressure and promoting hypertension-related end-organ damage.  
Interestingly, I found that T cells and in particular the T cell-derived cytokine IL-17a contribute to aortic 
stiffening. I have previously shown that mice lacking IL-17a are protected against hypertension.39 More 
recently, IL-17 has been shown to increase Rho kinase-mediated phosphorylation of the endothelial 
nitric oxide synthase, to promote endothelial dysfunction and to elevate blood pressure when 
administered parenteraly.67 In keeping with a role of inflammation in collagen deposition, I found that 
RAG-1-/- mice and IL-17a-/- mice are protected against aortic stiffening and collagen depostion during 
angiotensin II infusion, and that adoptive transfer of T cells to RAG-1-/- mice restores these 
abnormalities. I cannot exclude a role of cytokines other than IL-17a. As an example, TNF-α  often acts 
synergistically with IL-17 to promote inflammatory responses.  Recent studies showed that the TNF-α 
antagoinist etanercept reduces pulse wave velocity and aortic stiffness in patients with rheumatoid 
arthritis.79, 80 Our laboratory have also found that mice treated with the TNF-α antagonist etanercept and 
mice lacking IL-17a are protected against these vascular alterations.33 Thus, it is possible that this and 
other cytokines act in concert with IL-17 to promote aortic stiffening. 
It is likely that both CD4+ and CD8+ T cells contribute to aortic stiffening, as mice lacking either one 
alone had an intermediate phenotype. In particular, mice lacking CD8+ T cells had a reduction in aortic 
collagen accumulation caused by angiotensin II.  Likewise, adoptive transfer of only CD4+ cells  or only 
CD8+ T cells  to RAG-1-/- mice failed to restore aortic stiffening in response to angiotensin II. While 
CD8+ T cells are generally considered cytotoxic, it is now clear that CD8+ T cells produce substantial 
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amounts of cytokines and contribute to the inflammatory millieu.81, 82 In preliminary studies, I have found 
that angiotensin II infusion induces IL-17a production in several T cell subtypes in vivo.   
Our data also indicate that the mechanical effect of increased blood pressure also contributes to aortic 
stiffening.  Prevention of hypertension with hydralazine and hydrochlorothiazide prevented collagen 
deposition and the increase in aortic stiffness caused by chronic angiotensin II infusion.  These data do 
not separate mechanical effects from inflammation, because blood pressure lowering also prevented 
aortic leukocyte iniltration.  In keeping with this finding, there are numerous mechanisms by which 
mechanical stretch could affect vascular inflammation.  As examples, increased cyclical strain, similar 
to that observed in hypertension, activates the NADPH oxidase and NF-κB,  increases expression 
intracellular adhesion molecule-1 (ICAM1), and enhances adhesion of monocytes  to the 
endothelium.83,84 
Substantial research has focused on the role of TGF-β in tissue fibrosis and collagen deposition.  In 
several preliminary studies, I found that mRNA for TGF-β1 is not increased in aortas from angiotensin 
II-treated mice nor in cultured fibroblasts exposed to stretch.  This does not exclude the possibility that 
TGF-β activity is increased at a post-translational level in response to hypertension.  Latent TGF-β is 
processed to its active form by components of the inflammatory milieu, including matrix 
metalloproteinases, reactive oxygen species, thrombospondin-1 and integrins.85,86Related to this, our 
array analysis of the genes affected by hypertension provides insight.  This analysis showed that 
hypertension led to a 9-fold increase in MMP-2 and a 5-fold increase in thrombospondin-1.  These 
could contribute to post-translational activation of latent TGF-β in the absence of changes in its 
expression.  
In an effort to separate the direct effects of stretch and inflammation, I exposed cultured murine aortic 
fibrobasts to either cyclical stetch or IL-17a.  I selected fibroblasts because these represent the 
predominant cell in the adventital region where collagen deposition occurs.  Our data indicate that both 
of these stimuli induce mRNA of various collagen subtypes, all of which could contribute to aortic 
stiffening. Our data also indicate that p38 MAPK likely plays an important role in collagen expression 
both in cultured fibroblasts and in vivo.  Several studies has shown that inhibition of p38 blocks the pro-
fibrotic effects of mechanical stretch both in vitro and in vivo.  Park et al have shown that inhibition of 
p38 MAPK reduces cardiac and renal fibrosis in double transgenic rats harboring the human renin and 
angiotensinogen genes.76 Similarly p38 inhibition decreases cyclical stretch-induced collagen 
expression in isolated smooth muscle cells from WKY and SHR rats.78 Of note, p38 MAPK has been 
shown to bypass TGF-β signaling by transactivation of Smad-2/3 in mouse models of Marfan’s 
Syndrome and systemic inhibition of p38 blocks these effects.  In addition, increased activation of p38 
MAPK due to loss of MAPK phosphatase-1 activity induces expression of microRNA-21 (miR-21),87 a 
critical regulator of TGF-β signaling involved in renal and myocaridal fibrosis.88,89,90  MiR-21 inhibits 
Smad-7 and augments TGF-β signalling, enhancing its pro-fibrotic effects.91  Interestingly, miR-21 also 
contributes to renal fibrosis by regulating MMP9/TIMP-1. Thus, p38 MAPK plays a pivital role in the 
interaction between vascular inflammation and mechanical stretch.   
It is important to differentiate the causal relationship bewteen aortic stiffening and hypertension in vivo.  
Recent data from the Framingham study indicate that increases in pulse wave velocity precede the 
development of overt hypertension in the general population.92  Our study does not refute this, but 
suggests that once hypertension is initiated, aortic stiffening is markedly exagerated.  In keeping with 
this, in mice subjected to transverse aortic constriction, adventitial collagen deposition is observed 
proximal to the constriction, where pressures are elevated, but not distal to the constriction where 
pressures are normal.93  No matter the cause, stiffening of the proximal aorta leads to the loss of 
windkessel effect, further elevating systolic blood pressure.  Therefore, in the long run, aortic stiffening 
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and hypertension likely promote one another in a feed-forward fashion, ultimately leading to 
progressive elevations in systolic blood pressure.    
In the present study, the absolute amount of elastin present in the aorta was not affected by 
angiotensin II infusion, while the relative amount of elastin, expressed as a percent of total protein was 
reduced by about 50%.  This relative loss of elastin might also contribute to the reduced aortic 
compliance observed in angiotensin II-induced hypertension.  Loss of aortic elastin leads to aortic 
stiffening and hypertension in mice that are haploinsufficient for the elastin gene.14 It is also possible 
that while total elastin is not changed, elastin damage might occur  in the setting of angiotensin II-
induced hypertension.  Of note, MMP3, which was increased by 2.5 fold by angiotensin II infusion in our 
gene array analysis, has elastase activity, and could contribute to elastin fragmentation in hypertension.    
The striking deposition of collagen in the adventitial layer might not only promote vascular stiffness, but 
could also increase compression of vascular smooth muscle cells during systole.  Our in vitro studies 
showed that when intraluminal pressure is increased in a normal aorta, there is relatively equal 
expansion of both the lumen and the outer vascular media, thus preserving medial thickness.  In 
contrast, increasing intraluminal pressure in aortas from angiotensin II-treated mice led to an increase 
in the lumen that was substantially greater than that of the outer media, leading to comparession of the 
media.  This could lead to a condition in which vascular smooth muscle cells undergo cyclic 
compression during each cardiac cycle.  The impact of this on vascular smooth muscle function 
remains to be defined.   
In summary, this study provides new insight into mechansims of aortic stiffening in hypertension as 
depicted in Figure 14.  An important component of this process is a striking deposition of collagen in the 
adventitia.  Our data indicate that aortic stiffening is mediated by both mechanical factors assoicated 
with elevated pressures and by T cells and their release of inflammatory cytokines.  The p38 MAP 
kinase likely plays an important signalling role in response to these stimuli. Adventitial collagen 
deposition and aortic stiffening can not only be considered a form of end-organ damage in hypertension 
but can also further elevate systolic pressure, leading to progression of this disease. 
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  Oxidative	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  Activation	  and	  Aortic	  Stiffening	  in	  
Hypertension	  
 
3.1	  Chapter	  Abstract	  
T cells and interleukin 17A contribute to aortic stiffening, an important cause of systolic hypertension. 
Isoketals are lipid oxidation products that modify proteins to become immunogenic. I hypothesized that 
chronic vascular oxidative stress promotes T cell activation, aortic stiffening and hypertension via 
formation of isoketal-adducts. Mice with excessive vascular production of reactive oxygen species 
(tgsm/p22phox mice and mice with targeted deletion of the extracellular superoxide dismutase) develop 
vascular collagen deposition, aortic stiffening and hypertension with age. T cells of tgsm/p22phox mice 
produce high levels of IL-17A and IFN-γ. Crossing tgsm/p22phox mice with lymphocyte-deficient mice 
eliminated vascular inflammation, aortic stiffening and hypertension and adoptive transfer of T cells 
restored these processes. Isoketal-protein adducts were increased in aortas, dendritic cells and 
macrophages of Tgsm/p22phox mice. Autologous pulsing with tgsm/p22phox aortic homogenates promoted DCs 
of tgsm/p22phox mice to stimulate T cell proliferation and production of IFN-γ, IL-17A and TNF-α. 
Scavenging with tempol or 2-hydroxybenzylamine (2-HOBA) normalized blood pressure and prevented 
vascular inflammation, aortic stiffening and hypertension. Scavenging superoxide or isoketals also 
reduced formation of isoketals, and prevented DC and T cell activation. These results define a novel 
pathway linking vascular disease to immune activation. The resultant vascular inflammation promotes 
collagen deposition, aortic stiffening and age-related hypertension. Isoketal scavenging may prove 
useful in preventing these processes. 
Keywords: Oxidative stress, inflammation, collagen deposition and aortic stiffening 
 
3.2	  Introduction	  
The normal aorta expands to accommodate a portion of the ejected blood during cardiac contraction, 
and then recoils during cardiac relaxation. This capacitance or “Windkessel” function of the aorta 
reduces systolic pressure and maintains diastolic pressure and perfusion to the periphery. In several 
conditions, including aging, autoimmune diseases, cigarette smoking, diabetes, obesity and 
hypertension per se, the aorta stiffens, leading to loss of the Windkessel function and systolic 
hypertension. Pulse wave velocity, a surrogate measure of aortic stiffness, predicts untoward outcomes 
in aged and hypertensive humans.57, 94 A recent analysis of the Framingham population indicated that 
aortic stiffening is a precursor of hypertension.10 
A potential common feature of the many conditions associated with aortic stiffening is vascular oxidant 
stress. Clinically, plasma levels of myeloperoxidase and F2-isoprostanes, markers of oxidation, 
correlate with arterial stiffening in humans.95 Studies in experimental animals have implicated reactive 
oxygen species (ROS) in fibrotic changes in the blood vessel, lung, skin and other tissues.26, 96 In 
addition to oxidative events, chronic inflammation is associated with of arterial stiffness in humans.62, 64, 
80 Patients with systemic lupus erythematosus, rheumatoid arthritis and psoriasis exhibit increased 
aortic stiffness, and TNF-a antagonists improve parameters of aortic stiffness in patients with 
rheumatoid arthritis.97, 98 I have shown that hypertension is associated with infiltration of immune cells 
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into the peri-adventitial fat and activation of T cells that release pro-inflammatory cytokines such as IL-
17A, IFN-γ and TNF-α.33, 39 IL-17A induces collagen synthesis in fibroblasts via activation of p38 MAP 
kinase.99 IFN-γ also promotes hypertension-related fibrosis in the heart, arteries and the kidney.42 
A potential mechanism linking oxidative injury to immune activation and inflammation relates to 
oxidative modification of self-proteins. In particular, isoketals, alternatively referred to as 
isolevuglandins or γ-ketoaldehydes, are formed from fatty acid oxidation and undergo a pyrrolation 
reaction with protein lysines.100 Pyrrole modified proteins become auto-antigens and can illicit antibody 
formation.101 Our laboratory has recently shown that hypertension is associated with accumulation of 
isoketal-adducted proteins within dendritic cells (DCs). These adducts markedly enhance DC 
expression of the co-stimulatory molecules CD80 and CD86 and enhance DC production of IL-6, IL-23 
and IL1b.47 Moreover, DCs modified in this fashion robustly drive T cell activation and can prime 
hypertension when adoptively transferred to naïve mice. In this study, I found that hypertension 
stimulates DC production of reactive oxygen species, suggesting that lipid oxidation leading to isoketal 
formation was occurring inside the DC. Whether or not DCs can acquire oxidatively modified proteins 
produced by other cells remains undefined. Such a process could link oxidative injury in other cells to 
immune activation, and might explain how oxidative stress leads to vascular inflammation and 
ultimately aortic stiffening. In the present studies, I employed mice with chronic vascular oxidative 
stress to define a novel pathway which links oxidative damage to immune activation via formation of 
immunoreactive isoketal protein-adducts, vascular inflammation, aortic stiffening and hypertension. 
These experiments provide new insight into how diverse conditions diminish aortic compliance and 
ultimately cause hypertension. These findings also provide potential therapeutic options for treatment or 
prevention of aortic stiffening.  
	  
3.3	  Materials	  and	  methods	  
Animals:  The Institutional Animal Care and Use Committee at Vanderbilt approved all experimental 
protocols.  Male wild type and tgsm/p22phox mice were studied at 3, 6 and 9 months of age.  For 
measurement of blood pressure, 6 mice at each age were implanted with telemetry units. Ten days 
later, blood pressure was recorded for 10 minutes every hour for three days.  In additional (n = 6) 
tgsm/p22phox mice, tempol or 2-hydroxybenzylamine was administered in the drinking water from 4 to 9 
months of age. In some experiments, 3 month-old tgsm/p22phox mice x RAG-1-/- mice underwent adoptive 
transfer of T cells as described previously.33, 99, 102 Nine month-old tgsm/p22phox mice x RAG-1-/- mice, with 
or without T cell reconstitution, were used for blood pressure and vascular stiffness measurements. 
SOD3loxp/loxp x tgsm/p22phox mice and SOD3loxp/loxp x Cre-/- mice are treated with tamoxifen (3 mg/20 kg, 
dissolved in corn oil) via 5 consecutive intraperitoneal injections at 3 month of age and are studied at 9 
month of age.103 
Ex vivo measurement of aortic stiffness: For studies of vascular stiffness, the descending thoracic 
aorta was mounted on cannulas at the in situ length in calcium-free buffer.71 Intraluminal pressure was 
increased in a step-wise fashion while video microscopy was used to follow outer and inner diameter. 
Diameters were recorded with every increment of 25 mmHg from 0 to 200 mmHg. Stress-strain 
relationships were calculated as described by Baumbach et al.71 
Measurement of aortic collagen: Aortic collagen was visualized by Masson’s trichrome staining as 
described previously, with minor modifications.99 Isolated thoracic aortas were digested in 6 N HCl at 
105 ˚C for 48 hours before hydroxyproline was quantified.72-74 
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Flow cytometry: Single cell suspensions were prepared from aortas as previously described.99, 102 
Briefly, the entire aorta with surrounding perivascular fat was minced with fine scissors and digested 
with 1 mg/mL collagenase A, 1 mg/ml collagenase B, and 100 ug/ml DNAase I in phenol-free RPMI 
1640 medium with 5% FBS for 30 min at 37°C, with intermittent agitation. Fc receptors were blocked 
with CD16/CD32 for 20 min at 4°C (BDbiosciences, clone 2.4G2) prior to the staining of surface 
markers. The antibodies used were: Amcyan anti-CD45, PE anti-F4/80, Pacific Blue anti-CD19, APC-
Cy7 anti-CD3e, APC anti-CD4 and PE-Cy7 anti-CD8a. 1 x 106 cells were incubated with 1.5 µl of each 
antibody in 100 µl of FACS buffer for 35 minutes. The cells were then washed twice with FACS buffer 
and immediately analyzed on a FACSCanto flow cytometer with DIVA software (Becton Dickinson). 
Dead cells were eliminated from analysis using 7-AAD (BD Phermingen). For each experiment, we 
performed flow minus one (FMO) controls for each fluorophore to establish gates. Data analysis was 
performed using FlowJo software (Tree Star, Inc.). 
Intracellular staining of spleen cells: 1 x 106 spleen cells were resuspended in RPMI medium 
supplemented with 5% FBS and stimulated with ionomycin and phorbol myristate acetate and brefeldin 
A at 37°C for 5 hrs. Dead cells were excluded from analysis with a fixable Violet dead cell stain.  The 
following surface antibodies were employed for staining T cells: BV510 anti-CD45, PerCP-Cy5.5 anti-
CD3 antibody, PE-Cy7 anti-CD8, APC-H7 anti-CD4. Intracellular staining was then performed with the 
Cytofix/CytopermTM Plus fixation/permeabilization solution kit (BDbiosciences) using PE anti-IL17A and 
FITC anti-IFN-γ antibodies (eBioscience). In some experiments, macrophages, dendritic cells and 
monocytes were gated using APC anti-CD11b, PE anti-MerTK, APC-Cy anti-CD11c, PerCP-Cy5.5 
MHC II/I-A b, PE-Cy anti-CD64, Amcyan anti-F4/80, Alexa Fluor 700 anti-Ly-6C as previously 
described.104A single-chain antibody, D11 ScFv, was conjugated to Alexa Fluor 488 for the detection of 
isoketals in these cells. 
Measurement of isoketals: Six-micron sections were obtained from paraffin-embedded aortas and 
stained with D11 ScFv as previously described.47, 105 Isoketals in mouse aortas were also measured as 
the isoketal-lysyl-lactam adducts using mass spectrometric analysis as previously described.47, 100 
T cell proliferation assay: Aorta homogenates were obtained from WT mice, tgsm/p22phox mice or 
tgsm/p22phox mice chronically treated with tempol or 2-HOBA. Protein concentrations were determined in 
these samples using Bradford assay. CD11c+ DCs were isolated from total splenocytes of WT mice 
using a magnetic cell sorter and a commercially available kit (Miltenyi Biotec). This is an acceptable 
method to isolate essentially all DCs from mouse splenocytes. One million DCs were exposed to 100 
mg aortic protein for 2 hours in RPMI 1640 with 10% FBS, 5% penicillin/streptomycin/fungizone and 5% 
Sodium pyruvate. These DCs were washed twice before being co-cultured for 7 days with pan T cells 
pre-labeled with CFSE. T cells were obtained from 9 month-old WT mice or tgsm/p22phox mice that either 
been untreated or had been chronically treated with tempol or 2-HOBA in the drinking water. Various 
combinations of aorta homogenate and T cells were employed as described in Figure 9A and B. These 
cells were subjected to flow cytometry analysis and cytokines in the culture medium were measured by 
luminex. 
Statistical analysis: Data in the manuscript are expressed as the mean ± SEM. Comparisons of blood 
pressure over time and aortic mechanics were made using one-way ANOVA for repeated measures, 
followed by a Bonferroni post hoc test when significance was indicated. To compare the effect of 
treatments on various mouse strains, two-way ANOVA was employed. All other comparisons were 
made using one-way ANOVA. P values are reported in the figures. 
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3.4	  Results	  
3.4.1 Chronic vascular oxidative stress induces aortic stiffening and hypertension: As an initial 
approach to detecting aortic collagen, I studied tgsm/p22phox mice. These animals have smooth muscle 
targeted overexpression of p22phox, a docking subunit of all NADPH oxidase catalytic subunits.106 This 
leads to an increase in vascular Nox1 and an approximately 2-fold increase in vascular superoxide and 
hydrogen peroxide production. Masson’s trichrome staining revealed minimal collagen staining in the 
aorta of wild-type (WT) mice at either 3, 6 or 9 months of age (Figure 15A-B). In contrast, aortic 
adventitial collagen content was increased in the tgsm/p22phox mice at 6 and 9 months of age. 
Hydroxyproline analysis confirmed that aortic collagen content was increased by about 2-fold at 6 and 9 
months of age in tgsm/p22phox mice  (Figure 15C).  
Mechanical properties of the aortas of WT and tgsm/p22phox mice were studied in a pressurized vessel 
apparatus. Aortas from WT mice at 3, 6 and 9 months of age demonstrated identical responses to 
increasing pressure (Figure 15D). Aortas from 3 month-old tgsm/p22phox mice were similar to those of WT 
mice, but at 6 and 9 month of age, aortas of these mice demonstrated depressed pressure-diameter 
relationships. This was reflected by a leftward shift in the stress-strain curves (Figure 15E), indicating 
increased stiffness of the aortas of Tgsmp22phox mice at 6 and 9 month of age.  
Although aortic stiffening developed at 6 month of age in tgsm/p22phox mice, their blood pressure was 
normal at that age. At 9 months however, the tgsm/p22phox mice developed moderate hypertension, while 
WT mice remained normotensive (Figure 15F and 15G). Thus, in tgsm/p22phox mice, age-related aortic 
stiffening precedes the elevation of blood pressure, mimicking the relationship between these events in 
humans. 
The effects of oxidative stress on aortic stiffening and age-related hypertension were confirmed in mice 
with vascular smooth muscle targeted deletion of the extracellular superoxide dismutase (SOD3loxp/loxp x 
tgsmmhc/Cre mice), another model of vascular oxidative stress.48 At 9 month of age, these mice exhibited 
increased aortic adventitial collagen deposition compared to age-matched WT mice (Figure 16A and B). 
This was associated with development of aortic stiffening (Figure 16C and D) and elevation of blood 
pressure (Figure 16E and F). Collectively, these data support a role of vascular ROS in promoting 
vascular fibrosis, aortic stiffening and age-related hypertension. 
3.4.2 Oxidative stress-induced vascular inflammation contributes to age-related hypertension: 
We and others have previously demonstrated that vascular inflammation contributes to the 
development of hypertension and aortic stiffening.33, 39, 42, 65, 99 I therefore sought to determine if chronic 
oxidative stress promotes vascular inflammation in tgsm/p22phox mice. Flow cytometry of single cell 
suspensions revealed that total leukocytes, monocyte/macrophages, B cells, total T cells and CD4+ and 
CD8+ T cell subsets were all increased in aortas of 6 and 9 month old tgsm/p22phox mice compared to 
similarly aged WT mice (Figure 17A-N). Immunohistochemistry (IHC) using anti-CD3 indicated that T 
lymphocyte were predominantly located in the adventitia and perivascular fat of thoracic aortas in 
Tgsmp22phox mice at 6 and 9 month of age, compared to age-matched WT mice (Figure 17P).  
3.4.3 T lymphocytes are required for oxidative stress-induced collagen deposition, aortic 
stiffening and hypertension. Because T cells contribute to hypertension in other models, I crossed 
tgsm/p22phox mice with mice lacking Recombination Activation Gene-1 (Rag-1-/- mice), to generate 
tgsm/p22phox mice x Rag-1-/- mice. Unlike tgsm/p22phox mice, tgsm/p22phox mice x RAG-1-/- mice did not develop 
collagen deposition (Figure 18A-C), aortic stiffening (Figure 18D-E) or hypertension (Figure 18F-G). To 
further examine a role of T cells in aortic stiffening and hypertension in response to vascular oxidative 
stress, I adoptively transferred 2 X 107 T cells to tgsm/p22phox x Rag-1-/- mice at 3 months of age and 
allowed them to survive until 9 months of age. Adoptive transfer of T cells restored collagen deposition, 
aortic stiffening and blood pressure elevation in the tgsm/p22phox x RAG-1-/- mice, supporting an essential 
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role of T cells in the development of aortic fibrosis and hypertension induced by chronic vascular 
oxidative stress.  
3.4.4 Isoketals accumulate in the aorta and antigen presenting cells of Tgsmp22phox mice: Because 
isoketal-adducted proteins can act as auto-antigens and stimulate inflammatory responses,47, 101 I 
sought to determine if chronic vascular oxidant stress promotes their formation. Immunohistochemical 
staining using the single chain antibody D-11, revealed abundant isoketal protein adducts in aortas of 9 
month-old tgsmp22phox mice, but not WT mice (Figure 19A). Treatment of mice from 4 to 9 months of age 
with either the superoxide dismutase (SOD) mimetic tempol or the isoketal scavenging agent 2-
hydroxybenzylamine (2-HOBA) eliminated isoketal staining in the tgsm/p22phox mouse vessels.  
To further confirm the presence of isoketal-protein adducts in these vessels of tgsm/p22phox mice, I 
employed mass spectrometry in collaboration with Drs. L. Jackson Roberts and Sean S. Davies in the 
Department of Pharmacology at Vanderbilt University. Thoracic aortic homogenates of 9 month-old WT, 
tgsmp22phox mice and tgsmp22phox mice either untreated or treated with tempol or 2-HOBA, were 
homogenized and analyzed by liquid chromatography/mass spectrometry (LC/MS). Isoketals were 
identified as isoketal-lysine-lactam adducts in these measurements (Figure 19B). Aortic isoketal content 
was increased in Tgsmp22phox mice compared to WT mice, and this was prevented by treatment with 
either tempol or 2-HOBA. These data confirm that vascular oxidative stress induces formation of 
isoketals and that this can be prevented by treatment with either tempol or 2-HOBA.  
In additional experiments, I found that isoketals also accumulate in the antigen presenting cells (APCs) 
of tgsm/p22phox mice. Using a gating strategy recently described 104, macrophages were identified as 
CD64+MerTK+, and dendritic cells were selected from the remaining cells as CD11c+ and major 
histocompatibility complex class II (MHC II)+ cells (Figure 20). Monocytes were identified as 
CD11b+CD64+F4/80lowSSClow cells.  Virtually all monocytes were Ly-6C+ and most expressed MHC II. 
Intracellular staining for isoketals, using D11 conjugated to Alexa Fluor 488 revealed that DCs, 
macrophages and to a smaller extent, monocytes of tgsm/p22phox mice accumulate isoketal-protein 
adducts while cells of WT animals do not (Figure 19C-H). This was prevented by chronic treatment with 
either tempol or 2-HOBA.  
3.4.5 Scavenging of ROS prevents vascular inflammation, aortic stiffening and hypertension in 
tgsmp22phox mice. To determine if scavenging superoxide or isoketals prevents vascular oxidative stress-
induced aortic stiffening and hypertension I employed telemetry. Chronic treatment with either tempol or 
2-HOBA prevented aortic fibrosis in Tgsmp22phox mice at 6 and 9 months of age (Figure 21A-C).  Similarly, 
tempol and 2-HOBA prevented the development of aortic stiffening and age-related hypertension 
(Figure 21D-G), underscoring the importance of vascular ROS this disease.  These data support a role 
of vascular ROS in promoting vascular fibrosis, aortic stiffening and age-related hypertension. 
To determine if the protective effects of antioxidants were due to reduced vascular inflammation, I 
performed flow cytometry on the aortas of tgsm/p22phox mice treated with vehicle, tempol or 2-HOBA from 
4 to 9 months of age. Interestingly, tempol and 2-HOBA also markedly reduced the aortic infiltration of 
leukocytes (Figure 22A-C). The infiltrating CD45+ total leukocytes, F4/80+ monocyte/macrophages, 
CD19+ B cells, CD3+ total T cells and CD4+ and CD8+ T cell subsets were significantly reduced by 
either of these treatments (Figure 22D-I).  
3.4.6 Vascular oxidative stress promotes cytokine production by splenic T cells. We and others 
have previously shown that IL-17A and IFN-γ contribute to hypertension,39, 42, 107 and that IL-17A plays a 
critical role in aortic stiffening. I therefore sought to determine if T cells of mice with vascular oxidative 
stress produce IL-17A and IFN-γ. Splenic T cells from 9 months old WT and tgsm/p22phox mice were 
analyzed by flow cytometry using intracellular staining for the cytokines (Figure 23A). While WT T cells 
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produced minimal amounts of IL-17A, 5% of CD4+ T cells and 10% of double negative 
(CD3+/CD4-/CD8-) T cells of Tgsmp22phox mice produced this cytokine (Figure 23B-C and J-K). Likewise, 
IFN-γ-producing cells were doubled in all three subsets of T lymphocytes in tgsm/p22phox mice compared 
to WT (Figure 23F-G and M-O). Treatment with tempol or 2-HOBA normalized T cell production of IL-
17A and IFN-γ in tgsm/p22phox mice. These data suggest that vascular oxidative stress activates T cells 
and promotes their pro-inflammatory cytokine production. 
3.4.7 Protein homogenates of tgsm/p22phox mouse vessels are immunogenic: Our laboratory have 
shown that isoketal-protein adducts promote maturation and activation of dendritic cells in angiotensin 
II-induced hypertension, and that these activated DCs can drive proliferation of T cells from angiotensin 
II-treated mice.47 To determine if proteins from the aortas of tgsm/p22phox mice are immunogenic, I 
prepared aortic homogenates from WT and tgsm/p22phox mice at 9 months of age. These were used to 
pulse naïve DCs from WT mice for 2 hours and were then washed from the cells. As depicted in Figure 
24A, the DCs were then co-cultured with 1x107 T cells isolated from the spleen of either WT or 
tgsm/p22phox mice and pre-labeled with CFSE at a ratio of 1:10. Aortic homogenates of tgsm/p22phox mice, but 
not WT mice, supported survival of CD3+ (Figure 24B and F), CD4+ and CD8+ T cells (Figure 24C and 
G) when presented to T cells by DCs. DCs pulsed with tgsm/p22phox aortic homogenates also induced 
proliferation of CD4+ (Figure 24D and H) and to a lesser extent CD8+ T cells (Figure 24E and J), and 
increased the release of IL17A/F, IFN-γ and TNF-α into the medium (Table 3).  Chronic treatment of 
tgsm/p22phox mice with tempol or 2-HOBA reduced the immunogenicity of their aortic protein, as indicated 
by the diminished survival, proliferation and cytokine production of T cells in this assay (Figure 24B-J 
and Table 3).  Interestingly, T cells isolated from tgsm/p22phox mice, but not those from WT mice, survived 
and proliferated in response to the stimulation of immunogenic protein homogenate, suggesting that 
pre-exposure to isoketal-adducted antigens in vivo primed these cells for clonal expansion upon a 
second challenge.  
To determine if dendritic cells were functionally activated in these conditions, I also evaluated the 
polarizing cytokines released into the medium. When DCs exposed to tgsm/p22phox mice aorta 
homogenate were co-cultured with T cells isolated from tgsm/p22phox mice, there was a marked increase 
of GM-CSF, IL-1α, IL-1β, IL-6 and TGF-β1 and TGF-β3 (Table 3). These increases were blunted when 
DCs were primed with aortic homogenates from tgsm/p22phox mice chronically treated with tempol and 2-
HOBA, suggesting that antioxidant treatment reduced the immunogenicity of the vascular protein in 
these mice. Interestingly, tgsm/p22phox mice aorta homogenate failed to induce DCs to produce these 
cytokines if they were co-cultured with unresponsive WT T cells, suggesting that interactions with 
isoketal-primed T cells promote DC activation.  Other cytokines, such as IL-2, IL-12(p40), IL-12(p70), 
IL-21, IL-23 and TGF-β2 were either undetectable or not differentially produced across treatment 
groups. Collectively, these data suggest that vascular oxidative stress and the formation of isoketals 
induce DC activation, T cell proliferation and cytokine production.  
 
3.5	  Discussion	  
Aortic stiffening accompanies several common conditions including aging, hypertension, 
atherosclerosis, overt diabetes, obesity and cigarette smoking.52, 53, 95, 108 While aortic stiffening 
promotes systolic hypertension and predisposes to cardiovascular events, the precise mechanisms 
underlying its cause remain poorly understood. Our present study defines a new pathway in which 
vascular oxidative stress promotes formation of immunogenic isoketal protein adducts. These act as 
autoantigens that are presented to T lymphocytes by antigen presenting cells, leading to T cell 
activation. These activated T cells then infiltrate into the aortic periadventitial region and release 
cytokines that induce collagen deposition, leading to aortic stiffening and hypertension (Figure 25). 
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A recent analysis of the Framingham population revealed that aortic stiffening precedes the 
development of overt hypertension.10 In this regard, the tgsm/p22phox mouse mimics this sequence of 
events. At 6 months, aortic compliance was reduced in these animals prior to development of 
hypertension. At 9 months, these mice developed modest elevations of blood pressure, while WT mice 
remained normotensive at this time. I also observed aortic stiffening and hypertension in 9 month-old 
mice with targeted vascular smooth muscle deletion of SOD3. Our laboratory has previously shown that 
these mice have increased vascular superoxide production but are normotensive at 3 months.103 Taken 
together, data from these two models suggest that mice with chronic vascular oxidative stress 
recapitulate age related aortic stiffening and hypertension in humans, and suggest that chronic vascular 
oxidative stress might contribute to the human disease.   
In addition to oxidative events, aging is associated with the formation of advanced glycation end-
products (AGEs), which are generated from a reaction of sugars with proteins that accumulate in 
tissues with aging in the settings of insulin resistance and hypertension.30, 109 Like isoketals, AGEs also 
adduct lysine residues and crosslink matrix proteins, including collagen.110, 111 Of note, there is 
substantial interplay between AGEs and ROS. In human endothelial cells, ROS induced by high 
glucose stimulates the expression of receptors for AGEs (RAGEs) and RAGE ligands including S100 
calgranulins and high mobility group box 1.31 Drugs like ALT-711, a nonenzymatic breaker of AGE-
mediated cross-links, decrease arterial stiffness, improve endothelial function and slightly lower systolic 
blood pressure in humans and experimental animals.30, 32 It is likely that AGE deposition acts 
synergistically with the increase in collagen deposition to enhance arterial stiffening during aging. Of 
note, our laboratoey have previously shown that AGE-modified proteins do not share the 
immunogenicity of isoketal modifications.47 
Studies by our laboratory and others have implicated a role of T cell-derived cytokines in the 
development of tissue fibrosis and target organ damage in hypertension.33, 39, 42, 66, 99 In the present 
study, I found that vascular oxidative stress induces production of IL-17 by spleen T cells. Moreover, 
DCs primed with aortic homogenates from tgsm/p22phox mice markedly activated T cells from this same 
strain, but not WT mice. This activation profile included not only proliferation but also robust production 
of IL-17A, TNF-a and IFN-γ. These observations support a pathway in which vascular oxidative stress 
leads to formation of isoketal-protein adducts that are taken up by DCs that in turn can activate T cells. 
Of note, I have previously shown that IL-17A induces fibroblast production of collagen via activation of 
p38 MAP Kinase. Similarly, Valente et al have shown that IL-17A stimulates mouse cardiac fibroblast 
migration and proliferation via a p38 MAP kinase pathway.112 IFN-γ also mediates cardiac inflammation 
and fibrosis in angiotensin II-infused WT mice and IFN-γ receptor deficient mice are protected from 
these changes.42 Similarly, TNF-α has been implicated in angiotensin II-induced hypertension and TNF-
α antagonist treatment improves parameters of aortic compliance in humans with autoimmune 
disease.33, 97Thus, the milieu of Th1/Th17 cytokines stimulated by isoketal-adducted proteins likely 
promotes age-related aortic stiffening and hypertension.  
It is of interest to note that approximately 7 X 104 CD4+ cells persisted in the CFSE assay following 
stimulation of 107 T cells with DCs that had been pulsed with aortic homogenates. Given that these 
cells divided approximately 3 to 4 times (figure 24D), it is likely that they were derived from 
approximately 7 X 103 original T cells. Thus, approximately 0.01% of total T cells from the tgsm/p22phox 
mice seem capable of responding to antigens in their own aortic homogenates. These findings are in 
keeping with our recent observation that an oligoclonal population of T cells respond to angiotensin II-
induced hypertension.113 The fact that WT T cells did not respond to DCs pulsed with tgsm/p22phox aortic 
proteins suggests that these animals have not accumulated memory cells capable of this response, 
while tgsm/p22phox mice possess such cells. In accord with this conclusion, our laboratory recently showed 
that mice with angiotensin II-induced hypertension possess memory T cells capable of responding to 
isoketal-adducted proteins.47 
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Related to the above considerations, a striking finding in the current study is the marked production of 
cytokines, including IL-1β, IL-6, TGF-β1 and GM-CSF, by DCs primed with tgsm/p22phox aortic 
homogenates when exposed to T cells from tgsm/p22phox mice. This finding suggests that not only do DCs 
stimulate T cell proliferation and cytokine production, but also that T cells with T cell receptors that 
respond to isoketal adducts can reciprocally activate DCs. One such signal might involve co-stimulatory 
engagement of DC B7 ligands by T cell CD28, which our laboratory have previously shown to be critical 
for hypertension and T cell activation in this disease.102 In this regard, Orabona et al have shown that 
CD28 can stimulate DCs to produce IL-6, IFN-γ and to a lesser extent IL-23 in a B7 and p38 MAP 
kinase-dependent fashion.114 
Macrophages and monocytes may also function as antigen presenting cells and have the capability of 
triggering adaptive immune responses in addition to professional DCs.104 In the present study, I found 
an increase of total F4/80+ cells in the aorta of tgsm/p22phox mice with aging. In addition, I found that 
splenic macrophages and monocytes of tgsm/p22phox mice accumulate isoketals. We have previously 
shown that monocyte/macrophage like cells do not increase expression of the B7 ligands, CD80 and 
CD86 in concert with their acquisition of isoketal adducts as robustly as DCs, suggesting that they 
might not be as effective in T cell stimulation.47 
Despite the plethora of studies implicating ROS in diseases such as atherosclerosis, hypertension and 
diabetes, several large clinical trials using either vitamin E or combinations of antioxidants have failed 
to show any decrease in cardiovascular morbidity or mortality,21, 115 and high doses of vitamin E have 
paradoxically been associated with increased cardiovascular event rates,22 perhaps because ROS can 
have important signaling functions that modulate vascular tone, cell growth and survival,116-118 and are 
critical for innate immunity. It has been previously shown that these higher concentrations of vitamin E 
are required to suppress plasma F2 isoprostanes, which are formed in the same pathway as 
isoketals.119 It is therefore possible that agents such as 2-HOBA, which directly scavenge isoketals with 
a high rate constant and do not interfere with other ROS, will prove beneficial in treatment of disorders 
such as hypertension and aortic stiffening.  	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4.1	  Chapter	  Abstract	  
Aortic stiffening precedes hypertension and correlates with end-organ damage in the brain, heart and 
kidney. An important cause of aortic stiffening is adventitial collagen deposition, which impairs the 
capacitance function of large arteries. The sources of fibrosis in this condition are poorly defined. In the 
present study, I found that adventitial Sca-1+ progenitor cells proliferate and acquire a fibroblast-like 
phenotype in hypertension as determined by flow cytometry and immunofluorescence studies. CD31-
Sca-1+ cells isolated from angiotensin II-infused mice have upregulated expression of collagen 1a1, 
3a1, 5a1 and fibronectin-1 compared to those from sham treated mice. CD31+ endothelial cells and 
CD31-Sca-1- cells also expressed collagen and fibronectin-1 in response to angiotensin II infusion. 
Collagen I+CD45+ circulating fibrocytes were identified in the peripheral blood and were increased in the 
aortas of hypertensive mice. In WT mice transplanted with bone marrow from tgCAG-EGFP mice, 
hypertension caused EGFP+Col I+CD45+ cells to infiltrate the aortic adventitia where they co-localized 
with areas of collagen deposition. 45% of total Col I+ cells in the aorta were EGFP+ and therefore are 
derived from the bone marrow. The remaining 54% were EGFP-, representing vascular resident 
fibroblasts. In conclusion, fibroblast-like cells derive from Sca-1+ progenitors and infiltrating circulating 
fibrocytes are the two major contributors of arterial fibrosis in hypertension. 
Key words: Sca-1+ progenitors, circulating fibrocytes and collagen deposition 
 
4.2	  Introduction	  
Hypertension induces a striking deposition of collagen in the aortic adventitia. This fibrotic process 
results in loss of the “Windkessel function” of the proximal aorta and leads to systolic hypertension and 
target organ damage. Resident fibroblasts have been traditionally been thought to be a major source of 
tissue fibrosis in wound healing, atherosclerosis and vascular fibrosis. I have previously shown that T 
cell cytokine IL-17A and increased mechanical stretch, which are commonly encountered in 
hypertension, drive expression of multiple collagen subtypes in primary mouse aortic fibroblasts. This is 
mediated by activation of the p38 MAP kinase and inhibition of this enzyme prevents collagen 
deposition both in vitro and in vivo.99 Hypertensive stimuli such as reactive oxygen species also activate 
fibroblasts, promoting fibrinogenesis and tissue remodeling.28, 29 
 
Stem cell antigen-1 (Sca-1, alternatively known as lymphocyte antigen 6 complex, locus A or Ly-6A) 
positive progenitor cells reside in the vascular adventitia, which is a major site of collagen deposition in 
hypertension.99, 120 These pluripotent cells emerge during embryogenesis, persist into adulthood and 
represent roughly 20% of aortic adventitial cells.121, 122 In mouse aortas, they express several 
hematopoietic stem cell (HSC) markers, including Lin, c-kit and CD34.123, 124 Sca-1 cells are maintained 
by sonic hedgehog signaling (Shh) in the aortic adventitia, and in Shh-/- mice these cells are either 
absent or diminished in number.121 In healthy arteries of adult mice, Sca-1+ progenitors maintain 
endothelial and smooth muscles cells and generate vascular-like branching structures when cultured on 
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matrigel.124 However, under disease conditions such as atherosclerosis and vascular injury, these cells 
have the capacity to differentiate into mesenchymal phenotype and might contribute to tissue fibrosis.122 
Circulating fibrocytes are considered a specialized population of leukocytes that express collagen I and 
CD45.38, 125-127 These cells migrate to inflamed or injured tissues via chemotactic ligand-receptor 
interactions, and have been shown to play a role in wound healing and fibrosis of the heart, lung and 
kidney.38, 125-127 Once recruited to sites of inflammation, fibrocytes secrete additional chemokines that 
attract more fibrocytes and other leukocytes, including T cells, macrophages and dendritic cells.38, 128, 129 
Fibrocytes also promote tissue remodeling by depositing fibrotic proteins including collagen. In addition, 
by secreting TGF-beta1, they may also induce transformation of endothelial cells to a fibroblast-like 
phenotype, a phenomenon known as endothelial to mesenchymal transition.38, 130 
Thus, collagen-forming cells of the vessel can include resident fibroblasts, endothelial to mesenchymal 
transition, Sca-1 cells and recruitment of circulating fibrocytes. It is unclear however whether and how 
these different populations are involved the pathogenesis of aortic stiffening in hypertension. In the 
present study, I found that adventitial Sca-1+ progenitor cells acquire a collagen I-producing phenotype 
in hypertension, potentially contributing to collagen deposition and aortic stiffening. I also found that 
collagen I+CD45+ circulating fibrocytes infiltrate the large vessels and further promote arterial fibrosis in 
hypertension. These findings provide a new paradigm to support the roles of vascular and bone marrow 
origins of fibroblasts in response to vascular injury and inflammation. 
	  
4.3	  Methods	  
Animals: C57Bl/6, tgLy-6A/EGFP and tgCAG-EGFP mice were obtained from Jackson Laboratories at 12 
weeks of age. Hypertension was induced by infusion of angiotensin II (490 ng/kg/min) via osmotic 
minipumps for two weeks in WT and tgLy-6A/EGFP and 4 weeks in mice receiving bone marrow 
transplantation. The Institutional Animal Care and Use Committee at Vanderbilt approved all 
experimental protocols. 
Bone marrow transplantation (BMT):  Two weeks prior to BMT, 12 week old WT mice were 
transferred to sterile cages and fed sterile chow and acidified water (pH 2.0) containing 1 mg/ml of 
sulfamethazine-Na+ (Sigma) and 0.2 mg/ml of trimethoprim (Sigma) for prophylaxis. On the day of BMT, 
mice were lethally irradiated with a dose of 10 Gy 4 hours prior to BMT via a 137Cs irradiator (J. L. 
Shepherd and Associates, Glendale, CA). Bone marrow cells (2 x 107 cells) were obtained from femurs 
and tibias of tgCAG-EGFP mouse mice and were injected by the tail vein of recipient mice. The mice were 
then housed for 6 weeks to allow engraftment of the bone marrow.  Successful engraftment was 
confirmed upon sacrifice by flow cytometry of peripheral blood mononuclear cells for EGFP expression. 
Flow cytometry: Single cell suspensions were prepared from aortas as previously described.99, 102 
Briefly, the entire aorta with surrounding perivascular fat was minced with fine scissors and digested 
with 1 mg/mL collagenase A, 1 mg/ml collagenase B, and 100 ug/ml DNAase I in phenol-free RPMI 
1640 medium with 5% FBS for 30 min at 37°C, with intermittent agitation. Fc receptors were blocked 
with anti-mouse CD16/CD32 for 20 min at 4°C (BDbiosciences, clone 2.4G2) prior to the staining of 
surface markers. The antibodies used were: PerCP-Cy5 anti-CD45; PE anti-CD34; APC anti-CD34, 
APC-Cy7 anti-Sca-1/Ly-6A; PE-Cy7 anti-c-kit/CD117; Amcyan anti-CD31. All aortic cells were 
incubated with 1.5 µl of each antibody in 100 µl of FACS buffer for 35 minutes. The cells were then 
washed twice with FACS buffer and immediately analyzed on a FACSCanto flow cytometer with DIVA 
software (Becton Dickinson). Dead cells were excluded from analysis with a fixable Violet dead cell 
stain. Intracellular staining was then performed with the Cytofix/CytopermTM Plus 
fixation/permeabilization solution kit (BDbiosciences) using a mouse monoclonal antibody (Abcam) 
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conjugated to Alexa Fluor 488 or 647 (Molecular Probes). For each experiment, I performed flow minus 
one (FMO) controls for each fluorophore to establish gates. Data analysis was performed using FlowJo 
software (Tree Star, Inc.). 
Immunohistochemistry (IHC) and immunofluorescence: Aortic collagen was visualized by Masson’s 
Trichrome staining as previously described.99 Immunofluorescence staining was performed on fix-
perfused mouse aortas embedded in OCT. Six micron sections were sliced in a serial sequence. 
Samples were permeabilized with Triton X-100 (Sigma-Aldrich). Antigen blocking was performed with 
10% donkey serum (Abcam) prior to incubation with primary antibodies. These include monoclonal rat 
anti-Sca-1, mouse anti-collagen, polyclonal goat anti-EGFP and rabbit anti-Fsp-1 antibodies. Donkey 
polyclonal antibodies conjugated to Alexa Fluor 488, 555 or 647 were used for binding 1st antibodies. 
DAPI (Invitrogen) was added in the last wash following incubation with secondary antibodies. All slides 
were mounted with Prolong Anti-fade media (Life Technologies).  
Statistical analysis: Data are expressed as the mean ± SEM. Student’s t tests were used to compare 
the effects of sham and angiotensin II. Two-way ANOVA was used to analyze the effect of angiotensin 
II infusion on the gene expression of aortic cells as well as the density of circulating fibrocytes followed 
by a Bonferroni post hoc test when significance was indicated.  P values are reported in the figures. 
 
4.4	  Results	  
4.4.1 Aortic Sca-1+ cells develop fibroblast-like phenotype in hypertension. Using multicolor flow 
cytometry, I first examined the effect of chronic angiotensin II-induced hypertension on the presence of 
collagen-forming cells within the aorta. Sca-1+ cells were identified after excluding CD31+ endothelial 
cells which also express the Sca-1 marker (Figure 26A-D). Hypertension was associated with a 2.6-fold 
increase of CD31-Sca1+ progenitor cells (Figure 25D and I) compared to sham-infused mice. 
Interestingly, a small fraction of these progenitors produced collagen I at baseline, and these were 
more than doubled with hypertension (Figure 26F, H and J), suggesting hypertension promoted 
differentiation of these progenitors into a fibroblast-like phenotype. Of note, I observed a 4-fold increase 
of CD31+Col I+ cells in these experiments, suggesting that endothelial to mesenchymal transition 
contributes to vascular fibrosis in hypertension (Figure 26E and K). CD31-Sca-1-Col I+ cells were also 
increased in the aortas of angiotensin II-infused mice (Figure 26G and L). 
I have previously found that multiple collagen subtypes, fibronectin-1 and other matrix proteins are 
increased in aortas of hypertensive mice. To determine the relative contribution of various cell 
populations to arterial fibrosis, I isolated CD31+, CD31-Sca-1+ and CD31-Sca-1- cell fractions from 
mouse aortas using magnet-activated cell sorting (Figure 27A). In response to angiotensin II infusion, 
collagen 1a1, 3a1 and 5a1 were upregulated by 2-fold and fibronectin-1 by 4-fold in CD31+ cells, again 
supporting the notion that endothelial to mesenchymal transition contributes to arterial fibrosis in 
hypertension (Figure 27B-E). These collagen subtypes were also upregulated by 3-5 fold and 
fibronectin-1 by 2-fold in the CD31-Sca-1+ cells. Similarly, the CD31-Sca-1- cells markedly expressed 
collagen 1a1 and fibronectin-1 in response to hypertension, confirming a direct role of these cells in 
collagen deposition and aortic stiffening. 
In order to determine whether Sca-1+ progenitor cells differentiate into fibroblasts, I co-stained for Sca-1 
and collagen I on frozen sections of mouse aortas. To identify Sca-1+ cells in the aorta, I employed 
transgenic mice expressing a Sca-1-EGFP construct (tgLy-6A/EGFP). These hemizygous tgLy-6A/EGFP mice 
express EGFP in all adult hematopoietic stem cells and the expression of EGFP generally corresponds 
to Sca-1.131 As shown in Figure 27F and G, I observed a striking increase of total Sca-1+ cells in the 
aortic adventitia with hypertension compared to sham treated mice. Of note, these cells were closely 
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associated with the region of adventitial collagen deposition and some of them were observed to be 
actively producing collagen I, as indicated by the yellow co-localization. The number of Sca-1+Col I+ 
cells was increased 3-fold with hypertension (Figure 27G). Collectively, these data indicate that Sca1+ 
cells develop a fibroblast-like phenotype and contribute to collagen deposition in aortic stiffening and 
hypertension. 
4.4.2 Adventitial Sca-1+ cells proliferate during aortic stiffening. To determine whether the increase 
of Sca-1+ cells in the aortic adventitial was due to proliferation, I co-stained for Ki-67. As shown in 
Figure 28A, Ki-67 was undetectable in the aortic adventitial of sham-infused mice; in contrast, 
hypertension caused a marked increase of Ki-67+ cells that co-localize with Sca-1+ cells. 
Immunohistochemistry of serial sections of these aortas indicated that most of the Ki-67+ cells were 
embedded in the adventitial collagen layer (Figure 28B-D). These data suggest that Sca-1+ cells 
proliferate as they differentiate into collagen-producing cells in aortic stiffening. 
4.4.3 Bone marrow-derived circulating fibrocytes are recruited to aortic adventitia in 
hypertension. Fibrocytes expressing markers of leukocytes and mesenchymal cells circulate in the 
peripheral blood and migrate to injured tissues in response to chemokines.38 To determine if these cells 
contribute to aortic stiffening in hypertension, I identified all collagen I-producing cells in the peripheral 
blood mononuclear cells (PBMCs) and aorta using flow cytometry (Figure 29A). Col I+ cells were CD34-
CD31- and almost all expressed CD45. Very few of these cells expressed Sca-1 (less than 10%) or c-kit 
(1.5%). Circulating Col I+ cells and Col I+CD45+ cells are found at similar density in the peripheral blood 
of sham and angiotensin II-infused mice (Figure 29B, C and E), suggesting that these fibrocytes are 
maintained at a constant rate. Of note, hypertension is associated with a roughly 3-fold increase of Col 
I+CD45+ cells in the aorta, which may have been recruited from the circulation. These cells are also 
reminiscent of the CD31-Sca-1-Col I+ cells shown in Figure 26. 
Because hypertension is associated with increased expression of chemokines in the vascular cells, I 
sought to determine whether these circulating fibrocytes migrate to aortic adventitia during the onset of 
hypertension. Using bone marrow transplantation, I tracked cells derived from the marrow (Figure 30A). 
Flow cytometry analysis of PBMCs indicated that roughly 90% of circulating CD45+ leukocytes were 
EGFP+ in these mice, suggesting that the transplanted bone marrow was successfully engrafted in the 
recipients and was functional in hematopoiesis (Figure 30B). These mice also developed similar 
degrees of aortic stiffening in response to angiotensin II compared to WT mice (Figure 30B). Therefore, 
the bone marrow transplantation (BMT) procedure does not affect the pathogenesis of aortic stiffening 
in hypertension.  
I then co-stained for EGFP and fibroblast specific protein 1 (Fsp-1, also known as S100A4) on frozen 
sections of these transplanted mice (Figure 30C). There are very few EGFP+ cells in the adventitial 
region of sham-treated mice. In contrast, hypertension caused a 4-fold increase in recruitment of bone 
marrow-derived cells to the aortic adventitia (Figure 30C and E). The fibroblast marker, Fsp-1, was 
markedly increased in hypertension (Figure 30C and F). The number of cells positive for both EGFP 
and Fsp-1 were increased by 5-fold (Figure 30G), indicating these fibroblast-like cells are bone marrow-
derived. In addition, only 10% of EGFP+ cells were found to be Fsp-1 positive in sham mice, but this 
number increased to 40% with hypertension (Figure 30H), suggesting differentiation of these cells into 
fibroblast-like phenotype.  
I also examined collagen I-immunoreactivity to determine if these cells contribute to aortic fibrosis 
(Figure 30D). While there was minimal collagen (red) in sham treated mice, collagen immunoreactivity 
was markedly increased by chronic angiotensin II infusion. The location of the collagen deposition 
corresponded to Masson’s trichrome blue staining previously observed in normotensive and 
hypertensive animals.99 Of note, most of the bone marrow derived cells were found in this collagen 
layer. EGFP+Col I+  cells were detected by yellow co-localization, and represented 45% of total EGFP+ 
	   	   	  	  
26	  	  
cells. Taken together, these data support a role of bone marrow derived cells in the development of 
vascular fibrosis associated with aortic stiffening. 
4.4.4 Aortic Col I+ cells are derived equally from resident vascular sources and the bone marrow. 
I also determined the relative contribution of bone marrow-derived fibrocytes to resident fibroblasts 
within aortas of BMT mice infused with angiotensin II. I found that 45% of collagen I-producing cells 
were EGFP+ and therefore are derived from the bone marrow (Figure 31A and B). Most of Col I+EGFP+ 
cells were CD45+ (Figure 31A), suggesting they are recruited from circulating fibrocytes. Roughly 55% 
of all collagen I-producing cells were EGFP negative, representing resident vascular cells that are not 
derived from the marrow (Figure 31A and B). In Col I+EGFP- cells, 54.3% were CD31-Sca-1-, 40.8% 
were CD31-Sca-1+ and 4.5% were CD31+Sca-1+ (Figure 31A and C), representing the relative 
contribution of fibroblast-like cells originated from vascular sources.  
 
4.5	  Discussion	  
The present study demonstrates that there are at two major sources of tissue fibrosis that contribute to 
aortic stiffening in hypertension. Resident Sca-1+ progenitor cells differentiate into fibroblast-like cells in 
response to hypertensive stimuli and contribute to collagen deposition. In addition, bone marrow 
derived fibrocytes accumulate in the aortic adventitia and elaborate collagen (Figure 31D). Although 
these are two distinct sources of collagen, they contribute equally to arterial fibrosis in hypertension. 
Vascular resident Sca-1 cells are embryonically derived and continue to reside in the adventitia. Sca-1 
is expressed in all embryonic and adult mouse hematopoietic stem cells.131, 132 Sca-1+c-kit+CD41+ 
hematopoietic cells first emerge from the endothelium of dorsal aorta at embryonic date 10.5.132 
Adventitial Sca-1+ cells appear in the perivascular space between the ascending aorta and the 
pulmonary trunk between E15.5 and E18.5 and persist in this position until afterbirth.121 Adventitial Sca-
1+ cell emerge well after development of the tunica media, and likely represent embryonic 
hematopoietic stem cells that have arrived by the vasa vasorum.121 These cells remain in the vascular 
adventitia thereafter and expand in number during postnatal growth.121 It is noteworthy, however, that 
Sca-1+Lineage- progenitor cells also exist in the peripheral blood of adult mice.123, 133 In adult mice, 
whether there is exchange between the vascular resident progenitor cells and bone marrow-derived 
circulating progenitors remains controversial.134, 135 
 
In adult heart and blood vessels, resident Sca-1+ progenitor cells can differentiate into multiple lineages, 
including cardiomyocytes, endothelial and smooth muscle cells.121-124 There is evidence that these cells 
contribute to atherosclerotic lesions.122 In keeping with a role of these progenitors in vascular 
remodeling, I found that Sca-1+ cells in the aortic adventitial increase in number and promote arterial 
fibrosis by producing collagen subtypes and fibronectin-1 in response to hypertension. Likewise, others 
have shown Sca-1 expressing cells acquire a fibroblast-llike phenotype and demonstrate enhanced 
expression of connective tissue growth factor (CTGF) and fibronectin, contributing to fibrosis in aged 
murine skeletal muscle.136 
Circulating fibrocytes are recruited to injured tissue via chemoattactant molecules. One such signal is 
CCL-21, which recruits CCR7-expressing circulating fibrocytes to the injured kidney in unilateral ureter 
obstruction-induced renal fibrosis.38I and others have previously shown that hypertension causes 
leukocyte infiltration in the peri-adventitial adipose tissue and this infiltration is associated with an 
increase in intercellular adhesion molecule-1 (ICAM-1) and RANTES in the aorta. Furthermore, 
hypertension is also associated with increased T cell production of IL-17A and TNF-α.33 These 
cytokines synergistically upregulate the expression of multiple chemokines in human aortic smooth 
muscle cells,39 which may attract the migration of circulating fibrocytes to blood vessels in hypertension. 
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In support of this, I found increased the recruitment of these cells to the aortic adventitia of hypertensive 
mice where they actively synthesize collagen. 
Endothelial to mesenchymal transition contributes to tissue fibrosis in various tissues including the lung, 
heart, kidney and blood vessels.130, 137-140 In pressure-overload induced cardiac fibrosis, a condition 
closely related to hypertension, CD31+ endothelial cells become vimentin+ and express collagen I, III 
and fibronectin 28 days after surgery. Similarly, endothelial-originated fibroblasts express Fsp-1, α-
smooth muscle actin (α-SMA) and collagen I, and contribute to unilateral ureter obstruction-induced 
renal fibrosis. TGF-β1 is a potent signal that induces endothelial to mesenchymal transition and 
inhibition of TGF-β pathway prevents these changes.130, 137, 138 Interestingly, inflammatory molecules 
associated with hypertension, such as IFN-γ, TNF-α and IL-1β, can also promote endothelial to 
mesenchymal transition by suppressing expression of fibroblast growth factor receptor (FGFR), an 
inhibitor of TGF-β/TGF-βR1 signaling.141 In the current study, I found CD31+ cells isolated from the in 
the aorta of hypertensive mice moderately expressed collagen 1a1, 3a1, 5a1 and fibronectin-1, 
confirming a role of endothelial to mesenchymal transition in aortic stiffening.  
Of note, various sources of fibroblasts do not contribute equally to tissue fibrosis. LeBleu et al have 
gracefully demonstrated that tissue-resident (50%) and bone marrow-derived (35%) fibroblasts 
represent 85% of total myofibroblasts to unilateral ureter obstruction-induced fibrosis, while those 
derived from endothelial (10%) or epithelial cells (5%) account for the rest. In line with this, I found that 
45% of collagen I-producing cells in the aortas of hypertensive mice were derived from the bone 
marrow, while 54% derived from the vascular sources. Only 4.5% of Col I+EGFP- aortic cells were 
CD31+ (data not shown), suggesting that the contribution of endothelial to mesenchymal transition in 
aortic stiffening is limited. There are also temporal differences in the recruitment of these cells. As the 
first responders to tissue injury and inflammation, resident fibroblasts first become active in 
synthesizing collagen.142 As tissue injury and inflammation persist, bone marrow-derived fibrocytes may 
be recruited to further promote fibrosis. In severer situations, endothelial, epithelial and even pericytes 
subsequently transform into fibroblast-like cells.142 With the loss of functional cells, these events 
additively lead to irreversible tissue fibrosis and organ damage. 
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Chapter	  5	  
Conclusions	  
My dissertation research investigated the roles oxidative stress, inflammation and adaptive immunity in 
the pathogenesis of aortic stiffening in hypertension. My studies revealed a previously undefined 
pathway in which hypertensive stimuli, including angiotensin II, salt, and reactive oxygen species 
promote the activation of T cells and other components of the adaptive immunity via, at least in part, the 
formation of immunogenic isoketal-protein addcuts. DC-T cell crosstalk amplifies the effect of oxidative 
damage and initiates specific inflammatory responses. These involve the engagement of specific 
leukocytes populations that infiltrate the vasculature. Vascular inflammation is a critical stage during the 
onset of aortic stiffening, in which inflammatory cytokines such as IL-17A, IFN-γ and TNF-α may 
directly trigger the activation of arterial fibroblasts leading collagen production. Other cellular 
components such as Sca-1+ progenitors and circulating fibrocytes likely also participate in these fibrotic 
changes, ultimately leading to aortic stiffening and worsened hypertension (Figure 32). 
Kirabo et al has shown that hypertensive stimuli, such as angiotensin II or salt overload lead to 
neoantigen formation, in part by ROS formed in dendritic cells.47 This promotes activation of T cells, in 
particular CD8+ T cells, likely via isoketals presented by MHC I complexes. Class I complexes are 
loaded in the endoplasmic reticulum with peptides largely derived from self-proteins that have been 
degraded in the proteasome of all nucleated cells. When presented on the cell surface these send a 
protective “self” signal to immune cells such as Natural Killer (NK) cells, such that healthy cells will be 
ignored. Viral proteins in the cytoplasm can be loaded in MHC I. Likewise, oxidized proteins and 
peptides can be presented on MHC I, increasing immunogenicity.143There is also a phenomenon known 
as cross presentation or priming, in which exogenous proteins are taken up by phagocytosis, degraded 
in the phagosome and presented in class I complexes. My findings in the tgsmp22phox mice add to this 
paradigm. In this model of chronic vascular oxidative stress, isoketals are formed by ROS generated in 
the vascular smooth muscle cells; however, these preferentially promoted the activation of CD4+ T cells 
when presented by dendritic cells. In keeping with the concept CD4+ and CD8+ T cells have very 
different modes of activation and function; CD4+ cells are activated by antigens presented in type II 
major histocompatibility complexes (MHC II) on professional antigen presenting cells such as dendritic 
cells and mononuclear phagocytes. Antigens presented by MHC II complex are generally derived from 
extracellular proteins. The fact that more CD4+ cells than CD8+ cells proliferate when co-cultured with 
DCs pulsed with aorta homogenates from tgsmp22phox mice supports the concept that isoketals are 
presented by MHC II peptides in this context. Therefore, isoketals formed both inside and outside of 
dendritic cells can cause T cell activation and vascular inflammation in hypertension. 
 
Tissue fibrosis is often the consequence of chronic inflammatory responses. Chemokines made by 
inflammatory cells might recruit bone marrow derived fibrocytes, which are a major source of tissue 
fibrosis.38, 142 In support of this, Xia et al have showed that CXCL16 is expressed in the kidney in 
angiotensin II-infused mice in an NF-κB dependent manner.144 CXCL16 deficiency suppressed bone 
marrow-derived fibroblast accumulation and myofibroblast activation and reduced expression of 
extracellular matrix proteins in the kidneys of angiotensin II-treated mice. In addition, WT mice 
engrafted with CXCR6-/- bone marrow displayed fewer bone marrow-derived fibrocytes in the kidney 
after angiotensin II treatment compared to WT mice engrafted with CXCR6+/+ bone marrow.125 Similarly, 
CCL21 recruits circulating fibrocytes to the kidney by binding to CCR7 expressed on these cells and 
blocking this interaction reduces renal fibrosis.38 Hypertension causes infiltration of T cells to aortic 
adventitial.33, 99 Activated T cells secrete proinflammatory cytokines, including IFN-γ, IL-17A and TNF-α, 
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which in turn increase expression of chemokines that recruit bone marrow derived fibrocytes, promote 
vascular fibrosis and ultimately lead to aortic stiffening and severe hypertension.33, 39, 47, 49 
Aortic stiffening is both a cause and consequence of hypertension. Previous studies have established 
that aortic stiffening precedes hypertension both in experimental hypertension and epidemiological 
studies.9, 10 My findings in the Tgsmp22phox mice add to this literature and support the concept that 
stiffening of large capacitance arteries predispose to hypertension. My studies also support the concept 
that large arteries are targets of hypertensive end-organ damage. This is supported by the fact that 
normalization of blood pressure prevents the development of aortic stiffening and mechanical stretch 
alone induced the expression of collagen genes in cultured aortic fibroblasts. In human hypertension, it 
is likely that aortic stiffening and hypertension promote one another in a feed-forward fashion. On one 
hand, aortic stiffening causes loss of the “Windkessel” function of capacitance arteries, particularly the 
thoracic aorta, leading to elevation of the systolic blood pressure and rapid transmission of the stoke 
volume to the periphery. One the other, increased mechanical stretch associated with hypertension 
causes activation of vascular fibroblasts, resulting in aortic fibrosis characterized by the formation of a 
collagen “rind” in the adventitial region (Figure 32). This circumferential collagen deposition reduces 
vascular compliance and causes aortic stiffening. 
Fibrosis is an end-stage pathological change in many forms of tissue damage in the heart, lung and 
kidney. However, arterial fibrosis may not just a detrimental consequence of prolonged hypertension, 
the adventitial collagen deposition might actually be protective against the aneurysm development. In 
support of this notion, a recent study demonstrated that systemic neutralization TGF-β enhances 
development of angiotensin II-induced aneurysm formation in mice and markedly increases mortality 
due to aortic rupture.145 In keeping with this, mice in which IL-17 production is reduced by 
overexpression of suppression of cytokine secretion 3 (SOCS3) are markedly prone to developed 
aneurysms146 In my study, inhibition of p38 MAPK reduced adventitial collagen deposition and aortic 
stiffening but also promoted aneurysm formation. Furthermore, transglutaminase type 2-mediated ECM 
crosslinking also protects against the development of abdominal aortic aneurysm via the stabilization of 
extracellular matrix in post mortem analysis of human subjects.147 Therefore, aortic stiffening may 
represent a protective mechanism to prevent aortic aneurysm formation in the setting of hypertension.  
 
 
 
 
 
 
 
 
 
 
	    
	   	   	  	  
30	  	  
Table 1 Effect of hypertension on the expression of aortic ECM gene and adhesion molecules 
Symbol Extracellular Matrix Gene Sham 2^(-ΔΔCt) 
Angiotensin II 
2^(-ΔΔCt) 
Fold 
Increase 
Mmp2 Matrix metallopeptidase 2 0.21±0.04 1.88±0.12* 8.85 
Col1a1 Collagen, type I, alpha 1 1.10±0.60 9.40±2.73* 8.56 
Col3a1 Collagen, type III, alpha 1 6.19±2.14 42.92±3.77** 6.93 
Thbs1 Thrombospondin 1 0.19±0.03 0.93±0.12** 4.88 
Thbs2 Thrombospondin 2 0.08±0.03 0.39±0.06** 4.81 
Sparc Secreted acidic cysteine rich glycoprotein 1.79±0.79 8.08±0.96** 4.51 
Mmp11 Matrix metallopeptidase 11 0.0004±0.0001 0.0015±0.0005* 4.24 
Mmp14 Matrix metallopeptidase 14 0.03±0.01 0.11±0.02** 3.89 
Col5a1 Collagen, type V, alpha 1 0.30±0.13 0.99±0.22* 3.34 
Adamts2 
A disintegrin-like and 
metallopeptidase with 
thrombospondin type 1 motif, 2 
0.47±0.12 1.32±0.14** 2.83 
Itgam Integrin alpha M 0.013±0.004 0.036±0.011* 2.83 
Fbln1 Fibulin 1 0.05±0.01 0.14±0.03* 2.81 
Timp1 Tissue inhibitor of metalloproteinase 1 0.0001±0.00002 0.0003±0.00003* 2.46 
Mmp3 Matrix metallopeptidase 3 0.07±0.02 0.18±0.02** 2.45 
Itga2 Integrin alpha 2 0.003±0.001 0.006±0.001* 2.34 
Fn1 Fibronectin 1 1.33±0.48 2.79±0.57* 2.10 
Timp2 Tissue inhibitor of metalloproteinase 2 0.74±0.16 1.54±0.12* 2.08 
Adamts5 
A disintegrin-like and 
metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 5 
(aggrecanase-2) 
0.017±0.004 0.023±0.004 N.A. 
Adamts8 
A disintegrin-like and 
metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 8 
0.060±0.020 0.049±0.018 N.A. 
Ctnna1 Catenin (cadherin associated protein), alpha 1 0.37±0.06 0.38±0.04 N.A. 
Ctnna2 Catenin (cadherin associated protein), alpha 2 0.015±0.0093 0.0003±0.0095 N.A. 
Ctnnb1 Catenin (cadherin associated protein), beta 1 0.31±0.07 0.33±0.06 N.A. 
Cd44 CD44 antigen 0.09±0.01 0.17±0.01 N.A. 
Cdh1 Cadherin 1 0.0014±0.0008 0.0010±0.0005 N.A. 
Cdh2 Cadherin 2 0.026±0.012 0.042±0.012 N.A. 
Cdh3 Cadherin 3 <0.0001 <0.0001 N.A. 
Cdh4 Cadherin 4 0.0005±0.0002 0.0003±0.0002 N.A. 
Cntn1 Contactin 1 0.014±0.001 0.001±0.001 N.A. 
Col2a1 Collagen, type II, alpha 1 0.0002±0.0001 0.0149±0.0001 N.A. 
Col4a1 Collagen, type IV, alpha 1 0.70±0.27 1.11±0.28 N.A. 
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Symbol Extracellular Matrix Gene Sham 2^(-ΔΔCt) 
Angiotensin II 
2^(-ΔΔCt) 
Fold 
Increase 
Col4a2 Collagen, type IV, alpha 2 0.87±0.27 1.31±0.26 N.A. 
Col4a3 Collagen, type IV, alpha 3 0.006±0.003 0.008±0.002 N.A. 
Col6a1 Collagen, type VI, alpha 1 0.55±0.21 1.17±0.19 N.A. 
Vcan Versican 0.05±0.02 0.07±0.02 N.A. 
Ctgf Connective tissue growth factor 6.65±2.91 6.81±3.05 N.A. 
Ecm1 Extracellular matrix protein 1 0.21±0.07 0.28±0.05 N.A. 
Emilin1 Elastin microfibril interfacer 1 0.16±0.06 0.17±0.06 N.A. 
Entpd1 Ectonucleoside triphosphate diphosphohydrolase 1 0.19±0.08 0.09±0.07 N.A. 
Hapln1 Hyaluronan and proteoglycan link protein 1 0.004±0.002 0.002±0.002 N.A. 
Hc Hemolytic complement 0.0004±0.0003 0.0003±0.0001 N.A. 
Icam1 Intercellular adhesion molecule 1 0.029±0.006 0.036±0.004 N.A. 
Itga3 Integrin alpha 3 0.05±0.02 0.03±0.02 N.A. 
Itga4 Integrin alpha 4 0.12±0.07 0.12±0.07 N.A. 
Itga5 Integrin alpha 5  (fibronectin receptor alpha) 0.13±0.06 0.11±0.06 N.A. 
Itgae Integrin alpha E,  epithelial-associated 0.002±0.002 0.001±0.001 N.A. 
Itgal Integrin alpha L 0.011±0.010 0.004±0.001 N.A. 
Itgav Integrin alpha V 0.23±0.05 0.24±0.05 N.A. 
Itgax Integrin alpha X 0.004±0.002 0.007±0.002 N.A. 
Itgb1 Integrin beta 1 (fibronectin receptor beta) 1.80±0.53 1.65±0.50 N.A. 
Itgb2 Integrin beta 2 0.04±0.02 0.06±0.01 N.A. 
Itgb3 Integrin beta 3 0.11±0.03 0.05±0.03 N.A. 
Itgb4 Integrin beta 4 0.0015±0.0011 0.0005±0.0002 N.A. 
Lama1 Laminin, alpha 1 0.0001±0.0001 <0.0001 N.A. 
Lama2 Laminin, alpha 2 0.022±0.006 0.041±0.004 N.A. 
Lama3 Laminin, alpha 3 0.0031±0.0004 0.0037±0.0004 N.A. 
Lamb2 Laminin, beta 2 0.40±0.14 0.54±0.11 N.A. 
Lamb3 Laminin, beta 3 0.0004±0.0001 0.0008±0.0002 N.A. 
Lamc1 Laminin, gamma 1 0.07±0.02 0.13±0.03 N.A. 
Mmp1a Matrix metallopeptidase 1a  <0.0001 <0.0001 N.A. 
Mmp7 Matrix metallopeptidase 7 0.0001±0.0001 <0.0001 N.A. 
Mmp8 Matrix metallopeptidase 8 0.0001±0.004 <0.0001 N.A. 
Mmp9 Matrix metallopeptidase 9 0.009±0.006 0.003±0.006 N.A. 
Mmp10 Matrix metallopeptidase 10 <0.0001 <0.0001 N.A. 
Mmp12 Matrix metallopeptidase 12 <0.0001 <0.0001 N.A. 
Mmp13 Matrix metallopeptidase 13 0.0008±0.0002 0.0029±0.0006 N.A. 
Mmp15 Matrix metallopeptidase 15 0.009±0.004 0.008±0.003 N.A. 
Ncam1 Neural cell adhesion molecule 1 0.19±0.06 0.07±0.07 N.A. 
Ncam2 Neural cell adhesion molecule 2 0.0003±0.0001 0.0002±0.0002 N.A. 
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Symbol Extracellular Matrix Gene Sham 2^(-ΔΔCt) 
Angiotensin II 
2^(-ΔΔCt) 
Fold 
Increase 
Pecam1 Platelet/endothelial cell adhesion molecule 1 0.35±0.08 0.27±0.06 N.A. 
Postn Periostin, osteoblast specific factor 0.74±0.37 1.00±0.32 N.A. 
Sele Selectin, endothelial cell 0.0022±0.0004 0.0048±0.0005 N.A. 
Sell Selectin, lymphocyte 0.052±0.050 0.004±0.001 N.A. 
Selp Selectin, platelet 0.04±0.01 0.04±0.01 N.A. 
Sgce Sarcoglycan, epsilon 0.05±0.01 0.05±0.01 N.A. 
Spock1 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1 0.0019±0.0001 0.0011±0.0010 N.A. 
Spp1 Secreted phosphoprotein 1 0.01±0.01 0.20±0.04 N.A. 
Syt1 Synaptotagmin I 0.034±0.020 0.001±0.019 N.A. 
Tgfbi Transforming growth factor, beta induced 0.79±0.23 1.04±0.17 N.A. 
Thbs3 Thrombospondin 3 0.04±0.01 0.07±0.02 N.A. 
Timp3 Tissue inhibitor of metalloproteinase 3 0.03±0.01 0.03±0.01 N.A. 
Tnc Tenascin C 0.05±0.02 0.12±0.02 N.A. 
Vcam1 Vascular cell adhesion molecule 1 0.033±0.006 0.073±0.004 N.A. 
Vtn Vitronectin 0.02±0.01 0.02±0.01 N.A. 
 
Mice received either sham or angiotensin II treatment for 2 weeks. RNA was extracted from freshly 
isolated thoracic aorta after mice sacrifice. Matrix gene PCR array was performed to screen 84 aortic 
structural genes. 17 out 84 genes were upregulated in hypertension. Fold increase stands for the extent 
of gene upregulation compared to sham-treated mice based on ΔΔCt values. Data expressed as 
mean±SEM; *, p<0.05; p<0.01 vs. sham.  
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Table 2 Effects of IL-17a, angiotensin II and mechanical stretch on collagen expression by 
mouse aortic fibroblasts 
Treatment 
 Angiotensin II (100 nM) 
Col 1a1 Col 3a1 Col 5a1 Col 1a1 Col 3a1 Col 5a1 
Control 1.00±0.05 1.00±0.34 1.00±0.12 1.03±0.02 1.59±0.08 1.24±0.25 
IL-17a (100 ng/mL) 1.20±0.07 
 
4.63±0.66 
** 
1.89±0.10 
* 
1.12±0.12 
 
4.28±0.33 
** 
1.74±0.20 
 
5% Stretch 1.33±0.25 1.98±0.20 1.39±0.21 NA NA NA 
10% Stretch 2.24±0.24
** 
3.40±0.53 
** # 
2.45±0.37 
** 
2.80±0.34 
** 
7.50±1.43 
** 
2.68±0.62
** 
IL-17a (100 ng/mL) 
+ 10% Stretch 
2.16±0.13
** 
3.67±0.41 
** 
2.32±0.43 
** 
NA 
 
NA 
 
NA 
 
 
Primary mouse aortic fibroblasts were exposed to 5% or 10% cyclic stretch or exposed to IL-17a (100 
ng/mL) in the presence or absence of angiotensin II (100 nM) for 36 hours.  Relative quantity of mRNA 
was calculated based on the ΔΔCt value normalized to control.  Data are expressed as mean ± SE. 
The effects of IL17a and mechanical stretch are analyzed with one-way ANOVA, while the effect of 
angiotensin II by two-way ANOVA (n=3-6), * p<0.05, ** p<0.01 vs. control; # p<0.05 vs. angiotensin II. 
NA, not assessed. ECM, extracellular matrix. 	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Table 3 Vascular oxidative stress-induced dendritic cell activation and cytokine production 
Cytokine 
(pg/ml) 
WT * WT * Tgsm/p22phox * Tgsm/p22phox * Tgsm/p22phox  
+ Tempol * 
Tgsm/p22phox 
+ 2-HOBA * 
WT ** Tgsm/p22phox ** WT ** Tgsm/p22phox ** Tgsm/p22phox ** Tgsm/p22phox ** 
GM-CSF 12.99±1.42## 8.24±2.18## 23.47±11.17## 1450.50±620.01 45.04±28.71## 73.80±58.52## 
IL-1α 10.27±4.23# 5.17±1.71# 23.15±10.99 44.43±9.48 19.46±9.40 14.40±3.35 
IL-1β 7.33±2.58## 5.51±1.97## 12.51±4.59## 52.03±8.80 14.96±3.14## 17.41±11.26## 
IL-2 5.60±1.48 16.92±5.42 4.70±1.25 8.26±2.41 14.01±6.02 15.16±5.17 
IL-6 20.63±9.43## 28.64±12.70## 39.10±17.35## 1461.00±439.78 122.42±76.91## 215.62±126.10## 
IL-12(p40) 3.20±0.00 3.20±0.00 15.89±12.69 4.03±0.51 6.66±2.77 3.20±0.00 
IL-12(p70) 3.20±0.00 3.20±0.00 5.25±2.06 3.20±0.00 3.55±0.44 3.20±0.00 
IL-21 Undetectable Undetectable Undetectable Undetectable Undetectable Undetectable 
IL-23 Undetectable Undetectable Undetectable Undetectable Undetectable Undetectable 
TGF-β1 598.25±89.60## 779.67±79.89 733.25±50.09# 1078.00±121.93 807.20±56.93 860.60±75.65 
TGF-β2 Undetectable Undetectable Undetectable Undetectable Undetectable Undetectable 
TGF-β3 194.25±5.92 184.33±5.589## 189.00±1.68# 218.00±10.19 188.20±4.859## 190.00±3.54# 
IL-17A 20.06±2.27## 288.02±223.47# 30.24±11.86## 4433.50±1871.88 219.88±153.60## 298.38±197.49## 
IL-17F 4.23±0.00## 49.49±39.19## 15.80±11.57## 920.00±111.09 155.62±124.28## 142.70±88.87## 
IFN-γ 3.20±0.00## 38.47±30.54## 4.87±1.17## 3848.25±2662.32 50.53±52.53## 110.15±72.34## 
TNF-α 7.66±2.54## 10.69±5.07## 13.26±5.14## 83.45±8.10 21.73±5.57## 23.58±8.08## 
 
T cells from either 9 month-old WT or Tgsm/p22phox mice were stimulated with DCs pulsed by aorta homogenate of WT mice, 
Tgsmp22phox mice and Tgsmp22phox mice treated with tempol or 2-HOBA. Cytokines released into the culture medium were 
measured by a Luminex assay (n=6). IFN-γ was normalized by logarithmic transformation prior to one-way ANOVA.          
* Sources of aorta homogenate; ** Sources of T cells. # p<0.05, ## p<0.01 vs. Tgsm/p22phox mice.  
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Figure 1 Role of T cells in aortic collagen deposition in hypertension. A) Effects of angiotensin II-
induced hypertension on vascular collagen and elastin in WT and RAG-1-/- mice. Perfusion-fixed 
sections of the thoracic aortas were sectioned (6 mm) and stained with Hematoxylin and Eosin, 
Masson’s trichome and Van Gieson’s Elastica staining to highlight collagen (blue) and elastin (black). 
Scale bar indicates 100 µm.  B) Adventitial collagen area was quantified by planimetry. C) Aortic 
collagen quantification by hydroxyproline assay. Isolated thoracic aortas were digested in 6 N HCl at 
105 ˚C for 48 hours before hydroxyproline was quantified. D) Elastin was quantified biochemically by 
initial separation in 0.1 N NaOH at 90 ˚C for 30 min and subsequently by ninhydrin assay. Data were 
analyzed using two-way ANOVA (n=6-9). 
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Figure 2 T cells mediate angiotensin II-induced hypertension.A and B) Telemetry recordings of 
blood pressure in WT and Rag-1-/- mice receiving either sham or angiotensin II (490 ng/kg/min) 
infusions by osmotic minipump for 2 weeks. D, day time; N, night time. C) Flow cytometry confirming 
reconstitution of T cells in Rag-1-/- mice. Pan T cells were isolated from age-matched C57Bl/6 mice and 
transfered into Rag-1-/- mice via tail vein injection. Angiotensin II was administered three weeks after 
adoptive transfer of T cells. D and E) Hypertensive response to angiotensin II in Rag-1-/- mice after 
adoptive transfer of T cells. Data analyzed with one-way ANOVA with repeated measurements (n=7-9).  
F)Elastin was quantified biochemically by initial separation in 0.1 N NaOH at 90 ˚C for 30 min and 
subsequently by ninhydrin assay. G) Total protein was determined as the total of elastin and all other 
proteins. Ang II, angiotensin II.Data analyzed using two-way ANOVA (n=6-9). 
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Figure 3 Role of T cells in collagen deposition in mesenteric arteries in angiotensin II-induced 
hypertension. Perfusion-fixed sections of the mesenteric arteries were sectioned (6 mm) and stained 
with Masson’s trichome staining to highlight collagen (blue). Mesenteric arteries with diameters less 
than 100 µm were examined. Pan T cells were isolated from age-matched C57Bl/6 mice and transfered 
into Rag-1-/- mice via tail vein injection. Angiotensin II was administered three weeks after adoptive 
transfer of T cells. Scale bar indicates 100 µm. Ang II, angiotensin II. 
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Figure 4 T cells mediate angiotensin II-induced aortic stiffening.Freshly-isolated aortas were 
mounted on a myograph system in Ca2+-free buffer to determine pressure-diameter relationships. A-D) 
Compliance curves and stress-strain relationships were constructed from inner diameter and outer 
diameter. E and F) Inner and outer diameter of WT and RAG-1-/- mice measured at 25 mmHg step 
changes in pressure from 0-200 mmHg. Data were analyzed using one-way ANOVA with repeated 
measures (n=6-9). 
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Figure 5 Role of CD4+ and CD8+ T cells in aortic stiffening.CD4+ deficient and CD8+ deficient mice 
were infused with chronic angiotensin II (490 ng/kg/min) for 14 days. A) Masson’s trichrome staining. 
Scale bar indicates 100 µm. B) Adventitial collagen area determined by planimetry and C) 
hydroxyproline quantifcation. Data analyzed using two-way ANOVA. D and E) Compliance curves and 
stress-strain relationship for CD4-/- mice. F and G) Compliance curves and stress-strain curves for CD8-
/- mice. Data were analyzed using one-way ANOVA with repeated measures (n=6-8). 
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Figure 6 The effect of T cell subsets in angiotensin II-induced collagen deposition and aortic 
stiffening. Pan T cells, CD4+ T cells and CD8+ T cells were isolated from age-matched C57Bl/6 mice 
and transfered into Rag-1-/- mice via tail vein injection. Angiotensin II was administered three weeks 
after adoptive transfer of T cells. The effect of T cell sub-populations on collagen depostion (A and B) 
and aortic stiffening (C and D) are shown. Scale bar indicates 100 µm. Data for aortic stiffness were 
analyzed using one-way ANOVA with repeated measurements (n=5-7). Collagen deposition was 
analyzed using one-way ANOVA (n=5-7). Ang II, angiotensin II. 
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Figure 7 Role of IL-17a in aortic stiffening. IL-17a deficient mice were infused with chronic 
angiotensin II (490ng/kg/min) for 14 days. A and B)The thoracic aortas were fix-perfused for Masson’s 
trichrome staining and quantified for adventitia collagen staining. Scale bar indicates 100 µm. C) 
Segments of the thoracic aorta were digested in 6N HCl at 105 ˚C for 48 hours and measured for 
hydroxyproline concentration. Data analyzed using two-way ANOVA. D and E) Compliance curves and 
stress-strain curves for IL-17a-/- mice. Data analyzed using one-way ANOVA with repeated 
measures(n=6-8). 
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Figure 8 The effect of lymphocytes in DOCA-salt-induced aortic stiffening and collagen 
deposition.Mice were subjected to sham or deoxycorticosterone acetate (DOCA)-salt procedure for 3 
weeks. In DOCA-salt mice, 100 mg deoxycorticosterone acetate pellet were implanted subcutaneously 
following uninephrectomy. These mice were maintained on drinking water with 0.9% NaCl throughout 
the experiment. A-C)The effect of lymphocytes on adventitial collagen depostion. D-E)The effect of 
lymphocytes on DOCA-salt-induced aortic stiffening. Scale bar indicates 100 µm. Ang II, angiotensin II. 
Data for aortic stiffness were analyzed using one-way ANOVA with repeated measurements (n=5-7).  
Collagen deposition was analyzed using one-way ANOVA (n=5-7). 
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Figure 9 Antihypertensive treatment (antiHBP) prevents collagen deposition, aortic stiffening 
and T cell infiltration. Mice were treated with hydralazine and hydrochlorothiazide (320 mg/L and 60 
mg/L in the drinking water) concurrently with angiotensin II infusion. Hyd., Hydralazine, HCT, 
hydrochlorothiazide. A and B) Telemetry recording of blood pressures. D, day; N, night. The effects of 
blood pressure normalization on collagen depostion (C-E), aortic stiffening (F and G) and aortic 
inflammatory cell infiltration (H-L) are shown. Scale bar indicates 100 µm. Data for blood pressure and 
aortic stiffness were analyzed using one-way ANOVA with repeated measurements (n=8). Collagen 
deposition and flow cytometry were analyzed using one-way ANOVA (n=8). 
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Figure 10 Normalization of blood pressure in established hypertension and aortic stiffening:  the 
effects on collagen deposition and aortic stiffening. Mice were treated with sham or angiotensin II 
via osmotic minipump for 4 weeks (490 ng/kg/min). Reverse phase, blood pressure was normalized in 
the last two weeks of the 4 week angiotensin II infusion by hydralazine and hydrochlorothiazide given in 
drinking water (320 mg/L and 60 mg/L). A and B) Telemetry recording of blood pressures. The effects 
of blood pressure normalization on collagen depostion (C-E) and aortic stiffening (F and G) are shown.  
Scale bar indicates 100 µm. Ang II, angiotensin II. Data for blood pressure and aortic stiffness were 
analyzed using one-way ANOVA with repeated measurements (n=5-8). Collagen deposition was 
analyzed using one-way ANOVA (n=5-8). 
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Figure 11 Effect of cyclical stretch and IL-17a on aortic fibroblasts and role of p38 MAP kinase.  
Mouse aortic fibrobasts were exposed to various degrees of cyclical stretch or the T cell cytokine IL-17a 
(100 ng/mL) in culture for 36 hours. A-C) Both hypertensive mechanical stretch and IL-17a activated 
p38 MAPK in cultured mouse aortic fibroblasts. D-F) The effects of p38 inhibitor SB203580 (10 ng/mL) 
on mechanical stretch-induced expression of collagen subtypes in fibroblasts. G-I) The effects of p38 
inhibition on IL-17a-induced collagen expression. Data analyzed using one-way ANOVA(n=3-6). 
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Figure 12 P38 MAP kinase mediates collagen deposition and aortic stiffening in angiotensin II-
induced hypertension. A-C) Normalization of blood pressure prevented the activation of p38 MAP 
kinase in angiotensin II-infused mouse aortas. Data analyzed with one-way ANOVA (n=4-6). D and E) 
Effect of SB203580 on blood pressure.  D, day; N, night.  F-H) Effect of SB203580 on aortic collagen 
deposition. Data analyzed using one-way ANOVA (n=6-8). Mice received intraperitoneal injections of 
SB203580 (10 mg/kg/day) during angiotensin II infusion. Scale bar indicates 100 µm. I and J) Effect of 
SB203580 on aortic stiffening. Blood pressure and aortic stiffness were analyzed using one-way 
ANOVA with repeated measures (n=6-8). 
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Figure 13 Inhibition of p38 MAP kinase induced aneurysm formation in angitoensin II-infused 
mice. Mice received intraperitoneal injection of SB203580 (10 mg/kg/day) during angiotension II 
infusion. Maximal suprarenal aorta width was measured ex vivo. One-way ANOVA was performed for 
mean data (n=5). 
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Figure 14 Pathway showing interactions of mechanical stretch and inflammation in aortic 
stiffening. Increased mechanical stretch promotes perivascular T cell infiltration and activates p38 
MAP kinase, leading to adventitial collagen deposition. This reduces  aortic compliance and ultimately 
leads to loss of windkessel effect in large capacitance arteries such as the aorta. Aortic stiffening 
increases systolic pressure and promotes hypertension by positive feedback. 
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Figure 15 Tgsmp22phox mice develop age-related aortic stiffening and hypertension. A) Effects of 
aging on vascular collagen deposition in WT and Tgsmp22phox mice. Perfusion-fixed sections of the 
thoracic aortas were sectioned (6 µm) and stained with Masson’s trichome to highlight collagen (blue). 
Scale bar indicates 100 µm. B) Adventitial collagen area was quantified by planimetry. C) Aortic 
collagen quantification by hydroxyproline assay. D and E)Freshly-isolated aortas were mounted on a 
myograph system in Ca2+-free buffer to determine pressure-diameter relationships.  Stress-strain 
relationships were constructed from inner diameter and outer diameter. Inner and outer diameter of WT 
and Tgsmp22phox mice measured at 25 mmHg step changes in pressure from 0-200 mmHg. F and G) 
Telemetry blood pressure of WT and tgsmp22phox mice at 3, 6 and 9 month of age. Data were analyzed 
using two-way ANOVA(n=6-9). 
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Figure 16 Vascular oxidative stress induced by deletion of smooth muscle SOD3 also promotes 
aortic stiffening and hypertension. A) Masson’s trichrome blue staining and isoketal staining in 9 
month-old WT, SOD3loxp/loxp x Cre-/- and SOD3loxp/loxp x Tgsmmhc/Cre mice. Tamoxifen were administered at 
3 mg/20 kg in corn oil via intraperitoneal injection at 3 month of age. B) Hydroxyproline assay. C-D) 
Pressure diameter relationship and stress-strain relationship. E-F) Blood pressure measured by radio 
telemetry (n=6). 
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Figure 17 Flow cytometry analysis of inflammatory cells in the aorta of WT and Tgsmp22phox mice. 
Single cell suspension was prepared with freshly isolated mouse aortas via enzymatic digestion and 
mechanical dissociation. Only live cells and singlets were analyzed for vascular inflammatory cells.  
CD45+ Total leukocytes, F4/80+ macrophages, CD19+ B lymphocytes, CD3+ T lymphocytes and 
CD4+/CD8+T cell subsets were identified in the aorta of 9 month-old WT (A-D) and Tgsmp22phox mice (E-
H). I-N) Quantification of infiltating leukocyte subsets usintwo-way ANOVA (n=6-8). P)Thoracic aortas 
were fixed with 4% formalin, sliced into 6 µm sections and stained for CD3 to highlight T lymphocytes 
(dark brown). Scale bar indicates 100 µm. 
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Figure 18 T cells mediate age-related aortic collagen deposition, aortic stiffening and elevation 
of blood pressure in Tgsmp22phox mice. A-C) The effects of T lymphocyte deficiency and restoration on 
vascular oxidative stress-induced collagen deposition. Pan T cells were isolated from the spleen of 3 
month-old WT mice and adoptively transferred to age-matched Tgsmp22phox x Rag-1-/- mice to re-
constitute T cell population. Mice were kept till 9 month of age after adoptive transfer procedure. D and 
E) Role of T cells in the development of age-related aortic stiffening in Tgsmp22phox mice. F and G) T cells 
are required for the elevation of blood pressure in aged Tgsmp22phox mice. Collagen deposition was 
quantified using one-way ANOVA. Aortic stiffness and blood pressure were analyzed with one-way 
ANOVA with repeated measurements (n=6-8). 
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Figure 19 Tempol and 2-HOBA prevents the accumulation of isoketals in the aorta and antigen 
presenting cells in Tgsmp22phox mice. A) Fix-perfused mouse aortas were embedded in paraffin and 
subjected immunihistochemistry for isoketal staining. B) Stable isotope dilution multiple reactions 
monitoring mass spectrometry analysis of isoketal-lysine-lactam adduct in aortas. Representative 
LC/MS chromatographs from pooled samples for each group are shown. The top row shows multiple 
reactions monitoring m/z 479è84 chromatographs for isoketal-lysine-lactam (IsoK-Lys) in sample, 
while the bottom row shows multiple reactions monitoring m/z 487è90chromatograph for [13C615N2] 
internal standard for same samples. These are performed by William Zackert in Dr. L. Jackson Roberts’ 
laboratory and Dr. Sean S. Davies in the Department of Pharmacology. C-H) Intracellular staining for 
isoketals in spleen macrophages (C and D), dendritic cells (E and F) and monocytes (G and H) are 
shown. These data are analyzed using one-way ANOVA (n=6). 
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Figure 20 Gating strategy for macrophages, dendritic cells and monocytes in the spleen. Single 
cells suspension was prepared by mechanical dissociation and enzymatic digestion of mouse spleens. 
Dump chanel was set up to exclude dead cells, CD3+ T cells and CD19+ B cells. 
 
	   	   	  	  
55	  	  
	  
Figure 21 Antioxidant treatment prevents age-related aortic collagen deposition, aortic 
stiffening and elevation of blood pressure in Tgsmp22phox mice. A-C)Scavenging superoxide and 
isoketals prevents vascular oxidative stress-induced collagen deposition over aging. Tempol and 2-
hydroxybenzylamine (2-HOBA) were adminstered in drinking water from 3-9 month of age. D and E) 
Role of reactive oxygen species in the development of age-related aortic stiffening in Tgsmp22phox mice. F 
and G) Antioxidant treatment prevents the elevation of blood pressure in aged Tgsmp22phox mice. 
Collagen deposition was quantified using one-way ANOVA. Aortic stiffness and blood pressure were 
analyzed with one-way ANOVA with repeated measurements (n=6-8). 
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Figure 22 Antioxidant treatment prevents vascular inflammation in Tgsmp22phox mice. Tgsmp22phox 
mice were treated with tempol or 2-hydroxybenzylamine (2-HOBA) from 4 month of age until sacrifice at 
the end of 9 month. A-C)CD45+ total leukocytes, F4/80+ macrophages, CD19+ B lymphocytes, CD3+ T 
lymphocytes and CD4+/CD8+T cell subsets were identified in the aorta of these mice. D-I) 
Quantification of infiltating leukocyte subsets using one-way ANOVA (n=6-8). 
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Figure 23 Cytokine production of T cells in the spleen of 9 month-old WT and Tgsmp22phox mice. 
A)Gating strategy for isolation of T cell population from total spleenocytes. Single cell suspension was 
prepared with freshly isolated mouse spleens via enzymatic digestion and mechanical dissociation. 
Intracellular staining indicating IL-17A (B-E) and IFN-γ (F-I) production in T cell subsets in WT and 
Tgsmp22phox mice. J-O) Quantification of IL-17A and IFN-γ in T cell sub-populations. Bar graphs analyzed 
using one-way ANOVA (n=5-7). My colleague Dr. Mohamed A. Saleh performed these experiments for 
me. 
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Figure 24 DCs exposed to isoketals promote T cells proliferation and cytokine production. A) 
Experimental design was depicted. B and C and F and G, Flow cytometry was used to determine the 
number of live CD3+ T cells and CD4+/CD8+ T cell subsets. D and E and H-J) Representative flow 
cytometry profiles and bar graph showing percentages and numbers of proliferated (D and H) CD4+ T 
cells and (E and J) CD8+ T cells, as reflected by CSFE dilution assays (n= 6, *P < 0.05, **P < 0.01, 
one-way ANOVA). Tg. stands for tgsm/p22phox mice. Homo. stands for homogenate. 
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Figure 25 Proposed mechanisms for DC-T cell activation in aged related hypertension. 
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Figure 26 Hypertension increased the number of collagen I+ cells in the aorta. Flow cytometry 
analysis of whole aortas of mice receiving 14-day angiotensin II or sham treatment. A and B) Gating 
strategy showing that live single cells were analyzed. C and D) Sca-1+ cells identified in CD31- cells. E-
H) Collagen I intracellular staining in CD31+, CD31-Sca-1+ and CD31-Sca-1- cells. I-L) Quantification of 
CD31-Sca-1+ cells and collagen I+ cells. Student’s t test was performed where significance is indicated 
(n=6-8). 
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Figure 27 Aortic cells become fibroblast-like in hypertension. A) CD31+, CD31-Sca-1+ and CD31-
Sca-1- cells were isolated using magnet-activated cell sorting. B-E) Real-time PCR analysis of 
expression of collagen 1a1, 3a1, 5a1 and fibronectin-1 in cells fractions isolated from the aorta of sham 
and angiotensin II-treated mice (n=6). F and G) Immunofluorescence showing co-localization of Sca-1 
and collagen I in the aorta adventitia. 
	   	   	  	  
62	  	  
	  
Figure 28 Aortic adventitial Sca-1+ cells proliferate in hypertension. A) Co-localization of Sca-1+ 
cells with proliferation marker Ki-67 in the adventitial of hypertensive mice. B) Ki-67+ cells were 
identified in the areas of collagen deposition in the aortic adventitia (n=6). C and D) Quantification of Ki-
67+ cells in the aortic wall of sham and angiotensin II-infused mice. 
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Figure 29 Col I+CD45+ circulating fibrocytes migrate to hypertensive aortas. A) Gating strategy 
identifying circulating fibrocytes in the peripheral blood mononuclear cells (PBMCs). All col I+ cells were 
selected from live single cells, which were subsequently analyzed for CD34, CD31, CD45, Sca-1 and c-
kit. B and C) PBMCs positive for Col I or Col I/CD45 were found in the blood of sham and angiotensin II 
infused mice. D) Col I+CD45+ fibrocytes found in the aorta. E-F) Quantification of fibrocytes in the 
peripheral blood and in the aorta. 
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Figure 30 Bone marrow-derived cells express collagen I in the aortic adventitial of hypertensive 
mice. A) Scheme showing bone marrow transplantation technique. B) Circulating leukocytes were 
EGFP+ in WT mice receiving EGFP transgenic bone marrow and these mice develop similar degree of 
aortic collagen deposition to WT mice in hypertension. C-H) Bone marrow-derived cells migrate to 
aortic adventitia and acquire fibroblast markers. 
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Figure 31 Vascular fibroblasts and bone marrow derived-fibrocytes equally contribute to aortic 
fibrosis. A) Gating strategy showing Col I+EGFP+CD45+ fibrocytes in the aorta. B) The proportions of 
EGFP+ and EGFP- cells in the total aortic Col I+ cells. C) Relative contribution of fibroblast-like cells 
derived from vascular origins. D) Working hypothesis showing that the roles of arterial Sca-1+ 
progenitors and circulating fibrocytes in fibrosis and stiffening of the aorta in hypertension. 
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Figure 32 Working hypothesis summarizing findings of my dissertation research. This diagram 
depicts the interplay between oxidative stress, inflammtion and adaptive immunity the development of 
aortic stiffening and hypertension. 
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